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1. Introduction 
 
Oral administration is the most common route for drug administration. It is estimated 
that 40% or more of APIs identified through combinatorial screening programs are poorly 
soluble in water [1]. However, after oral administration, the absorption may be erratic and 
incomplete. Therefore it is a great challenge for the pharmaceutical technologists to formulate 
suitable therapeutic effect disposed products from these materials. Recently it would be 
advantageous if the pharmacokinetic properties of drug candidates could be predicted before 
clinical phases [2]. 
One of the prerequisites for successful oral drug therapy is sufficient intestinal 
absorption. The rate and extent of intestinal absorption are mainly dependent on the 
dissolution rate of the drug in the gastrointestinal fluids and the rate of transport across the 
intestinal membrane. [3]. These two factors were the base of the BCS [4]. Poorly water–
soluble drugs (BCS II and IV class) are associated with slow drug absorption leading 
eventually to inadequate and variable BA [4, 5]. There are several possibilities to modify the 
APIs to reach better physico–chemical parameters, thereby better BA (Fig. 1). The rate and 
extent of absorption of Class II compounds is highly dependent on the performance of the 
formulated product. These drugs can be successfully formulated for oral administration, but 
care needs to be taken with formulation design to ensure consistent BA [6]. 
 
Fig. 1 Formulation strategies of APIs belonging different classes of BCS to improve their BA 
[6] 
This thesis is based on investigations of an antihistamine drug, LOR belonging to the 
Class II of BCS to increase its solubility, dissolution rate and BA. 
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2. Bioavailability 
 
The BA of pharmacons is basically determined by their solubility and permeability. All 
drugs must possess some degree of aqueous solubility in order to be pharmacologically active, 
and they need to be lipophilic to be able to permeate biological membranes [7]. The rate–
limiting step of oral absorption is the dissolution by APIs with solubility < 0.1 mg/ml, e.g. 
drugs belonging in classes II and IV of the BCS [5, 8]. The solubility of ionizable compounds 
varies with the pH of the gastrointestinal juices, depending on their pKa [9]. The pH of the 
gastrointestinal fluids is therefore one of the most important factors influencing on the 
saturation solubility of ionizable drugs [10]. As the pharmacon proceeds along the 
gastrointestinal tract, it passes into a medium with somewhat higher pH. During 90% of a 
fasting state, the gastric pH is <3 [11]. The presence of food in the stomach can influence the 
release, dissolution and gastro–duodenal transport of a drug [12]. As the gastrointestinal pH 
can vary widely, the rate of dissolution of an ionizable pharmacon will also vary considerably. 
Only the dissolved drug is capable of absorption, so its BA, and hence the pharmacokinetic 
parameters will be very variable [13]. 
 
2.1. Solubility and dissolution rate 
 
First we need to distinguish between “kinetic” and “thermodynamic solubility”. By the 
kinetic solubility tests the compound is dissolved in an organic solvent (generally in DMSO), 
then added to the aqueous buffer until precipitation. In the case of thermodynamic solubility 
the aqueous solvent is added directly to solid crystalline material (the solid is in excess) and 
long mixing time is applied to ensure equilibrium (e.g. 24 – 72 hours). The kinetic solubility 
in general tends to be higher, than the thermodynamic, because the presence of DMSO helps 
to enhance solubility, there is no need to overcome the crystal lattice energy by water 
molecules [14, 15]. 
There is a difference between solubility and dissolution rate, too. Solubility is how 
much of a compound can dissolve in a solution. Dissolution rate is how fast a compound can 
dissolve into solution [14]. 
Intrinsic dissolution rate has been defined as ”the rate of dissolution of a pure 
pharmaceutical active ingredient when conditions such as surface area, temperature, agitation 
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or stirring speed, pH and ionic strength of the dissolution medium are kept constant” [16]. It is 
specific for the substance. The apparent dissolution rate reflects the liberation of drug from a 
dosage form [17]. 
Noyes and Whitney noticed that the rate of dissolution is proportional to the difference 
between the instantaneous concentration, C at time t, and the saturation solubility, Cs. This 
relationship was modified by Brunner, Tolloczko and Nernst (see Equation 1), who 
considered the exposed surface (S), the thickness of the diffusion layer (h), the volume of the 
dissolution medium (V) and the diffusion coefficient (D) [18].  
 
)(][ CC
hV
SD
dt
Cd
s −
⋅
⋅
=           Equation 1. 
 
Based on this equation, there are several possibilities for increasing the solubility and 
dissolution rate: 
• increasing the surface area; 
• decreasing the thickness of diffusion layer; 
• better wettability; 
• increasing the apparent solubility by suitable physiological conditions. 
 
There are several pharmaceutical technological methods to enhance the solubility and the 
dissolution rate, thereby the BA (Table 1). 
 
Table 1 Possibilities for the solubility enhancement 
Particle size 
reduction 
Dispersion 
in a carrier 
 
Amorphisation 
Molecular 
complexation 
 
Other methods 
• micronization 
• nanotechnology 
• interactive 
mixtures 
• SCF technology 
• solid 
solutions 
• solid 
dispersions 
• eutectic 
mixtures 
• with 
excipients 
• without 
excipients 
• CDs 
• terner systems 
(organic acids, 
macromolecules) 
• polymorphism 
• crystal habit 
• salt formation 
• cosolvents 
• oily solutions 
• emulsions, 
microemulsions 
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2.1.1. Particle size reduction 
 
The reduction of the particle size results in the rise of specific surface area, which 
effects favourably on the dissolution rate. 
Micronization is a term used to describe size reduction where the resulting particle 
size distribution is less than 10 µm. Micronization involves acceleration of particles so that 
grinding occurs by particle–to–particle impact or impact against a solid surface [19]. N. 
Resenack et al. enhanced markedly the dissolution rate of ibuprofen, itraconazole and 
ketoconazole by in situ micronization method [20]. 
Nanosuspensions are sub–micron colloidal dispersion of pure particles of drug, which 
are stabilized by surfactants. Nanosuspensions can be formed by bottom up techniques 
(building particles as in precipitation) or by top down methods (desintegration as in milling). 
In both case new surface area is formed. Therefore it has more free energy and system tends 
to agglomerate which is prevented by addition of surfactants. Surfactants cause high energy 
barrier and prevents particles coming together [21]. P. Kocbek et al. improved the dissolution 
rate of ibuprofen by formulation of nanosuspension. The dissolution rate proved to be higher 
for smaller drug particles, thus influencing the BA of the drug and improving safety for the 
patient by decreasing gastric irritancy [22]. 
If a free–flowing powder is mixed with a cohesive powder an interactive mixture can 
be obtained. The cohesive particles adhere to the free–flowing particles (now called carrier 
particles) to form interactive units [23]. An interactive mixture may not contain free 
aggregates of the cohesive powder, which means that all small particles must be adhered to 
the larger ones. The difference from an ordered mixture is instead that all carrier particles do 
not need to be of the same size and a different number of small particles attached to each one. 
A narrow size range of the carrier particles is preferred to avoid segregation of the interactive 
units [24]. Interactive mixtures can be used enhancing the dissolution of poorly soluble drugs. 
[25] B. Alway et al. improved the dissolution of diazepam in lactose interactive mixtures 
[26]. 
The SCF technology has many advantages. A pure component enters the supercritical 
status when both temperature and pressure are above its critical p and T values. In this region, 
the SCF exists in an intermediate phase between liquid and gas phases. The SCF is dense but 
highly compressible, particularly near the supercritical region. Thus, any change of pressure 
alters its density and consequently the solvent power [27]. The compound is dissolved in an 
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SCF solvent (usually CO2), then the solution gets into a special nozzle, where the pressure is 
rapidly decreased. So the solution becomes supersaturated, which resulted in precipitation of 
small particles [28]. V. Majerik et al. enhanced the solubility and dissolution properties of 
oxeglitazar by SAS technology. SAS is a type of SCF technology, where the fluid is used not 
for solvent, but antisolvent [29]. 
 
2.1.2. Dispersion in a carrier 
 
Many hydrophilic carrier can be applied for this purpose e.g. polyethylene glycol, 
polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA), crospovidone, PVP–PVA copolymer, 
cellulose derivatives, polyacrylates and polymetacrylates, urea, sugar, polyols and their 
polymers, emulsifiers, organic acids and their derivatives [5]. 
A simple eutectic mixture consists of two compounds which are completely miscible 
in the liquid state but only to a very limited extent in the solid state. When a mixture of A and 
B with composition of C is cooled, A and B crystallize out simultaneously; whereas when 
other compositions are cooled, one of the components starts to crystallize out before the other. 
When a mixture with composition C, consisting of a poorly soluble drug and an inert, highly 
water soluble carrier, is dissolved in an aqueous medium, the carrier will dissolve rapidly, 
releasing very fine crystals of the drug. The large surface area of the resulting suspension 
should result in an enhanced dissolution rate and thereby improved BA. 
Solid solutions are comparable to liquid solutions, consisting of just one phase 
irrespective of the number of components. In the case of solid solutions, the drug’s particle 
size has been reduced to its absolute minimum viz. the molecular dimensions and the 
dissolution rate are determined by the dissolution rate of the carrier [5].  
Solid dispersion differs from the solid solution in that the particle size is greater, non–
molecular. 
S.G. Kapsi et al. prepared solid solutions of itraconazole with different carriers and 
they observed better BA compared to marketed product [30]. C.S. Yong et al. improved the 
solubility of ibuprofen with menthol due to formation of an eutectic mixture. So ibuprofen 
will be in molecular distribution during the preparation of the suppository, therefore a 
solution–format of suppository can be prepared, a faster therapeutic effect can be achieved 
[31]. R. Ambrus et al. improved the solubility and permeability of poorly water–soluble 
niflumic acid by application of PVP [32]. 
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Polyvinylpyrrolidone  
 
PVP (Fig. 2) is an amorphous carrier and it is suitable for formulating solid solutions, glass 
solutions and amorphous precipitations with a crystalline API. The glass transition 
temperature (Tg) is high and for this reason PVPs have only limited applications for the 
preparation of solid dispersions by the hot-melt method. Due to their good solubility in a wide 
range of organic solvents, they are particularly suitable for the preparation of solid dispersions 
by the solvent method [33]. The aqueous solubility of the PVPs becomes poorer with 
increasing chain length, and a further disadvantage of the high Mw PVPs is their much higher 
viscosity at a given concentration, however they can be used for controlled release. [34]. The 
aim of the preparation of PVP solid dispersions is generally to transform the drug into the 
amorphous form and thus to achieve faster dissolution. Dispersions containing crystalline 
areas exhibit biphasic release profiles, with the amorphous areas dissolving quickly and the 
crystalline areas more slowly. For example, for a crystalline drug with a very poor aqueous 
solubility, the formation of an amorphous mixture with a water-soluble additive can provide 
an opportunity to enhance the dissolution and perhaps bioavailability [35]. 
 
Fig. 2 Structural formula of PVP 
 
2.1.3. Amorphization 
 
The amorphous state is lacking distinct crystalline structure or organization. A rigid 
material, whose structure lacks crystalline periodicity. The amorphization process can be 
processed by three ways: solvent method, hot–melt technology and milling technology. By 
the solvent method the API is dissolved in a suitable solvent then the solvent is evaporated 
rapidly. In case of hot–melt technology the API is melt, and then it is suddenly cooled or the 
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excipient is melt and in this melt the API can be dissolved and then it is cooled down. The 
theoretical base of the milling technology is that the cohesion in the crystal can be disrupted 
by appropriate external forces, and the crystalline state is left off. Since the amorphous state 
has higher energy than the crystalline form, the amorphous materials due to thermodynamic 
principles are going to recrystallize beyond a certain date. To stabilize the amorphous form, 
we can use crystallization–inhibitors (PVP, sugars, sugar–alcohols etc.) [36]. The amorphous 
state is a good technique to improve solubility of poorly soluble drugs [37]. 
 
2.1.4. Complexation 
 
A complex implied a reversible association of molecules, atoms or ions through weak 
chemical bounds. From viewpoint of drug formulation complexation can be sorted as follows 
[17]: 
• metal complexes 
Also known as coordination compounds. The cohesion is valence force or 
intermolecular force. Such compounds are e.g. citric acid, tartaric acid or EDTA 
(ethylenediamine-tetraacetate) which complexes the decomposition catalysing hard 
metals. 
• molecular complexes 
The bond is given by hydrogen–bonding or dipole–dipole interaction. Such complexes 
are e.g. caffeine–sodium benzoate or sodium–salicylate. 
• inclusion complexes 
The cohesion is intermolecular forces. The most frequently applied complex forming 
agents are cyclodextrins and latterly the calixarenes. A calixarene is a macrocycle or 
cyclic oligomer based on a hydroxyalkylation product of a phenol and an aldehyde. 
The word calixarene is derived from calix or chalice because this type of molecule 
resembles a vase and from the word arene that refers to the aromatic building block. 
Calixarenes have hydrophobic cavities that can hold smaller molecules or ions [38]. 
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2.1.5. Changing the crystal habit 
 
Crystals can be rated into needle–like, isometric, tabular, lamellar and columnar 
morphological classes based on their habit. The different crystal habit can cause substantial 
differences in the dissolution rate [39]. The different crystal habits are chemically the same, 
but they differ in many physicochemical properties e.g. melting point, density, flow 
properties, solubility properties. R. Adhiyaman et al. got the conclusion that because the in 
vitro dissolution data are good predictor of in vivo performance therefore it can safely 
concluded that the improved dissolution rate of the modified crystals will give better BA and 
better therapeutic activity clinically [40]. 
 
2.1.6. Polymorphism, pseudopolymorphism 
 
Polymorphism is the ability of a solid material to exist in more than one form or 
crystal structure by the same chemical structure. The different crystal forms of the same 
compound have different free energy, therefore their thermodynamic activity is variable. 
Polymorphs can differ in melting point, melting enthalpy, solubility, dissolution rate, 
bioavailability, permeability, chemical reactivity, habit, stability, density, refraction index, 
electrical conductivity, heat of solution and from other utilization and processing aspect 
important properties [39, 41, 42]. These different physical properties may affect the 
therapeutic efficacy, toxicity, BA, pharmaceutical processing and stability of the drug product 
[43]. The relative stability of polymorphs depends on their free energies, such that a more 
stable polymorph has a lower free energy. Under a defined set of experimental conditions 
only one polymorph has the lowest free energy. This polymorph is the thermodynamically 
stable form and the other polymorph is termed a metastable form. The metastable form is 
sometimes desirable on account of its special properties, such as higher BA, better behaviour 
during grinding and compression, or lower hygroscopicity. However a metastable form has a 
thermodynamic tendency to reduce its free energy by transforming into stable form [44]. 
Pseudo–polymorphism is a kind of polymorphism that is characterized by solvate 
compounds, including water solvates (hydrates) [42]. 
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2.1.7. Prodrugs 
 
A prodrug is a bioreversible chemical derivative of an active parent drug. Chemical 
modification of the poorly water–soluble parent drug can result in a water–soluble prodrug. 
The synthesis of N–alkoxycarbonyl prodrugs of anthelminthic mebendazole has been 
shown to increase its aqueous solubility by two orders of magnitude. Amino acid ester 
prodrugs have been synthesized both to improve intestinal membrane permeability and 
increase aqueous solubility of acyclovir. The poorly water–soluble etoposid has shown some 
evidence for improved oral BA in preliminary studies utilizing phosphate ester prodrug. The 
addition of the phosphate ester functionality on phenytoin resulted in a prodrug stable in 
aqueous solution with over a 7000–fold increase in aqueous solubility [45–49].  
 
2.1.8. Salt formation 
 
Salt formation is the most common and effective method of increasing solubility and 
dissolution rates of acidic and basic drugs [50]. The process is a simple way to modify the 
properties of a drug with ionizable functional groups to overcome undesirable features of the 
parent drug. Salts are formed when a compound that is ionized in solution forms a strong 
ionic interaction with an oppositely charged counterion, leading to crystallization of the salt 
form [51]. 
H.S. Gwak et al. improved the dissolution rate of a BCS II drug, piroxicam by salt 
formation with mono–, di– and triethanolamin. In the three salts the highest dissolution rate 
belonged to the monoethanolamin–salt at pH = 6.8, however there was no difference at 
pH = 1.2 [52]. 
 
2.2. Permeability 
 
 
The absorption of an orally administered drug involves the extent and rate of transfer 
of the drug from the GI–tract to the portal blood supply. Absorption is a complex process that 
is influenced not only by physicochemical properties (e.g. solubility, charge, lipophilicity, 
permeability, etc.) of the drug but also by physiological GI properties (e.g. intestinal transit 
times, active transporters, gut wall metabolism etc.) and formulation differences. Because a 
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significant number of small molecules that are synthesized in drug discovery laboratories are 
transported across the GI epithelial barrier by a passive transcellular mechanism, the solubility 
and permeability of the drug are key surrogate absorption markers [53]. 
There are several methods to model the absorption and to screen the permeability. The 
Fig. 3 shows these possibilities in the order of predictability, throughput and cost–
effectiveness. Recently there are many computational programs (in silico) which have a great 
database and can predict some parameters such as pKa, logP, logD, solubility etc. from the 
formula of a molecule. Unfortunately the reliability of the obtained data is very limited. The 
measured physico–chemical parameters predict primarily the passive transport. The PAMPA 
is one of the most often applied methods in the early stage of drug discovery because it is easy 
to carry out, about 100 compounds can be studied in the same time and requires small amount 
of samples. Its primal disadvantage is that it can predict only the passive transport. If the 
active transport plays also a role, the suitable method is the Caco–2 model, but it is costly and 
slow. The in vivo animal tests approach considerably well the human absorption, but there are 
minor differences between the absorption parameters. Certainly the most effective and the 
most expensive way is the human assay [54]. 
 
 
Fig. 3 Measuring and predicting possibilities of absorption 
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3. Cyclodextrins 
 
CDs were discovered approximately 100 years ago. They are cyclic, non–reducing 
oligosaccharides built up from six, seven or eight glucopyranose units [55]. CDs are obtained 
by starch bioconversion using cyclodextrin glucosyltransferase. This enzyme is produced by a 
variety of bacteria, mainly by several species of Bacillus, Klebsiella or Thermoanaerobacter. 
Different types of starch can be used as substrate, but potato starch is the most commonly 
used for CD production. Maize starch and wheat starch are also used but they contain a higher 
percentage of amylase, which gives lower yields of CD than amylopectin [56]. 
Owing to their apolar cavity, they are able to form complexes with molecules, or part 
of them, changing the physicochemical properties, such as solubility and stability of the guest 
compounds [55]. Guest molecules can be solid, liquid or even gaseous. 
CDs are capable of forming inclusion complexes with compounds having a size 
compatible with the dimensions of the cavity. The extent of the complex formation depends, 
however, also on the polarity of the guest molecule. 
The characteristic feature of the host molecule is that the binding sites are oriented to 
the same spatial direction, whereas in the guest molecule the binding sites are diverging in the 
complex. 
CD monographs can be found in several Pharmacopoeias [57–59]. 
 
Table 2 CDs in Pharmacopoeias 
General 
name 
Name in the 
Pharmacopoeia 
In which part Pharmacopoeia 
α-CD Alfadex In Monographs Ph. Eur., USP 34 – NF 29, BP 2012 
 α -Cyclodextrin  In Reagents Ph. Eur., USP 34 – NF 29, BP 2012 
β-CD Betadex In Monographs Ph. Eur., USP 34 – NF 29, BP 2012 
 β-cyclodextrin In Reagents Ph. Eur., BP 2012 
γ-CD Gamma Cyclodextrin In Monographs USP 34 – NF 29 
HPBCD Hydroxypropylbetadex In Monographs Ph. Eur., USP 34 – NF 29, BP 2012 
 
Hydroxypropyl-
betacyclodextrin 
In Reagents Ph. Eur., USP 34 – NF 29, BP 2012 
DIMEB 
Dimethyl-beta-
cyclodextrin 
In Reagents Ph. Eur., USP 34 – NF 29, BP 2012 
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3.1. Derivatives 
 
It is well known that derivatisation changes the physical and chemical properties of the 
CDs, modifying their solubility, complex–forming capacity, thermal properties and chemical 
stability. Most common substituents used in CD derivatives: methylated, acetylated, 
carboxymethylated, hydroxypropylated, naphtylethyl carbamate, 3,5–dimethylphenyl 
carbamate, p–toluoyl, α–methylbenzamine, naphthylethylamine, pyridylethylene diamine, 
nitropyridylethylene diamine, phenyl carbamate, cationic β–CDs [60]. 
More than 1500 different CD derivatives have been described in the literature. One 
can distinguish hydrophilic, lipophilic and ionizable derivatives. Chemical substitution 
elongates the CD torus in an axial direction by introducing larger substituents. Modification 
of the 2– or 3–hydroxyl group results in disruption of the hydrogen bonding occurring around 
the ring of the CD molecule. The disruption allows more interactions of these hydroxyl 
groups with water molecules, resulting in altered solubility [61]. 
From the viewpoint of the optimization of pharmacotherapy, drug release should be 
controlled in accordance with the therapeutic purpose and the pharmacological properties of 
active substances. Various CD derivatives have been used in order to modify drug release in 
oral preparations. The hydrophilic and hydrophobic CDs are useful for the immediate release 
and the prolonged release type formulations, respectively. Recently, highly hydrophilic CD 
derivatives, such as HPBCD, 6–O–maltosyl–β–CD and sulfobutyl–β–CD have been used to 
obtain an immediate release formulation, which is readily dissolved in the GI tracts, 
promising an enhancement of oral BA of poorly water–soluble drugs. Hydrophobic CDs 
having a weak acidic group (e.g. 6–O–(carboxymethyl)–O–ethyl–β–CD) are less soluble in 
water at low pH but soluble in neutral and alkaline regions. Under the control of this pH–
dependence, the delayed release dosage form which passes from the stomach into the higher 
pH environment would experience increased drug release. Most of the slow–release 
preparations have been aimed to provide a constant blood level for a long period of time. For 
this purpose, hydrophobic CDs such as alkylated and acylated derivatives are useful as slow–
release carriers for water–soluble drugs. When the stomach is one of the important absorption 
sites, there should be no lag time in drug release from the dosage form. To attain an efficient 
BA for such acidic drugs, a double–layer tableting was useful, consisting of hydrophilic CDs 
as the fast–release portion and hydrophobic cellulose derivatives as the slow–release portion 
[62]. 
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3.2. Physico–chemical properties of natural CDs and CD derivatives 
 
The natural CDs consist of 6, 7 or 8 D–glucopyranose units – by α–1,4–glycoside 
linkage – and are referred to as α–, β– and γ–CD, respectively. Because of the 4C1 chair 
conformation of each glucopyranose units, the whole molecule has the shape of a hollow 
truncated cone. The interior of the cavity is composed of hydrogen atoms of C3, C5 and 
oxygen atoms of the glycoside linkage, which makes the intracavity hydrophobic while the 
exterior of the cavity is hydrophilic due to assembling large numbers of alcoholic hydroxyl 
groups [63]. As results CDs can form host–guest inclusion complexes by weak intermolecular 
interaction. 
 Unsubstituted, native CDs are crystalline, non–hygroscopic, homogenous substances. 
 
Table 3 Physical and chemical characteristics of CDs [60] 
 α–CD β–CD γ–CD DIMEB 
Glucose units 6 7 8 7 
Internal diameter (nm) 0.47 – 0.53 0.60 – 0.65 0.75 – 0.83 6 A 
Depth of cavity (nm) 0.79 0.79 0.79 >0.79 
pKa value 12.3 12.2 12.1 * 
Mw 972 1135 1297 1331 
water solubility         
(mg/ml 25 ˚C) 
145 18.5 232 Op.: 295-300 
Crystal water (%, w/w) 10.2 13.2 – 14.5 8.13 – 17.7 * 
* no data available 
 
The C2 hydroxyl group of one glucopyranose unit can form a hydrogen bond with the 
C3 hydroxyl group of the neighbouring glucopyranose unit. In the β–CD intermolecular 
hydrogen bonding occurs between the secondary hydroxyl groups which reduces the number 
of hydroxyl groups capable of forming hydrogen bonds with the surrounding water 
molecules, so it can explain the observation that β–CD has the lowest solubility of all native 
CDs [60, 64]. 
Substituted β–CD derivatives are characterized by much higher solubility. Random 
substitution of the hydroxyl groups, even by hydrophobic moieties such as methoxy functions, 
will result in dramatic improvements in their solubility. The main reason for the solubility 
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enhancement is that the random substitution transforms the crystalline CDs into amorphous 
mixtures of isomeric derivatives [7]. DIMEB is prepared from β–CD by the selective 
methylation of all C2 secondary hydroxyl groups and all C6 primary hydroxyl groups (C3 
secondary hydroxyl groups remain unsubstituted) [65]. DIMEB is soluble in organic solvents, 
and very soluble in cold water – because it is strongly hydrated in the sense of Pauling’s 
clathrate model of liquid water – 20–25% solutions of increased viscosity can readily be 
prepared. An uncommon property of DIMEB is that the homogenous and clear solution will 
suddenly crystallize on heating (above 50 ˚C). The feasible explanation of the negative 
solubility coefficient of methylated CDs in water that the hydration structure breaks down at 
elevated temperature. Hence, the hydrophobic DIMEB molecules become less soluble and 
aggregate, as could be expected from the hydrophobic effect, leading finally to crystallization 
In contrast to the native CDs, DIMEB has surfactant activity [55, 66]. 
The thermoanalytical measurements indicated that CDs have no well–defined melting 
point, but from about 250 to 400 ˚C they begin to decompose. It has been frequently shown 
that the thermal stability of CD derivatives depends on the type, location and number of any 
substituents. As previously mentioned CDs are not hygroscopic, but form various stable 
hydrates [60]. 
CDs are insoluble in most organic solvents; but they are soluble in some polar, aprotic 
solvents. CDs glass transition occurs at about 225 to 250 ˚C. The glass transition temperature 
varies with the degree of substitution. Strong acids such as hydrochloric acid and sulphuric 
acid hydrolyze CDs. CDs are very stable against bases [61]. 
In forming inclusion complexes, the physical and chemical properties of both the drug 
molecule and the CD molecule can be altered. Co–solvents will increase the solubility of a 
poorly water soluble drug in a nonlinear fashion with respect to co–solvent concentration. The 
linear relationship between solubility and CD concentration has a number of advantages, one 
of which is the lack of precipitation of the formulation on dilution in contrast to the co–
solvent method. It is important to realize that the kinetics of inclusion complex formation and 
dissociation between a CD and a drug molecule is fast. The half–lives for 
formation/dissociation are much less than one second and occur at rates very close to 
diffusion controlled limits [67]. 
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3.3. Complexation mechanisms 
 
Complexation of molecules to CDs occurs through a non–covalent interaction between 
the molecule and the CD cavity. This is a dynamic process whereby the guest molecule 
continuously associates and dissociates from the host CD. CD inclusion is a stoichiometric 
molecular phenomenon in which usually only one molecule interacts with the cavity of the 
CD molecule to become entrapped. Inclusion complex formation can be regarded as 
“encapsulation” of the drug molecule, or at least the labile part of the molecule. Many 
techniques are used to form CD complexes, like co–precipitation, slurry complexation, paste 
complexation, damp mixing, heating method, extrusion and dry mixing [61]. 
The driving forces for inclusion complexation are both enthalpic and enthropic in 
nature and not fully understood [67]. The main driving force for complex formation, at least 
in the case of β–CD and its derivatives, appears to be release of the enthalpy–rich water 
molecules from the CD cavity which lowers the energy of the system. These water molecules 
located inside the central cavity are replaced by either the whole drug molecule, or more 
frequently, by some lipophilic structure of the molecule. However, other forces, such as van 
der Waals interactions, hydrogen bonding, hydrophobic interactions, release of structural 
strains and changes in surface tension, may also be involved in the complex formation. No 
covalent bonds are involved in the complex formation and drug molecules located in the 
cavity are in a very dynamic equilibrium with free drug molecules out in the solution. In 
aqueous solutions drug/CD complexes are constantly being formed and broken at rates very 
close to the diffusion controlled limit [64]. 
 
3.4. Cyclodextrins and drug delivery 
 
In general, formulation techniques that increase the apparent aqueous solubility of 
Class II and Class IV drugs without decreasing their lipophilicity will enhance their 
absorption through biological membranes. These techniques include particle size reduction, 
salt formation, solid dispersion, melt extrusion, spray–drying, and complexation, as well as 
drug solutions in microemulsions, liposomes and non–aqueous solvents. The chemical 
structures of CDs, their molecular weight and their very low octanol/water partition 
coefficient are all characteristics of compounds that do not readily permeate biological 
membranes. Only the free form of the drug, which is in equilibrium with the drug/CD 
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complex, is capable of penetrating lipophilic membranes. The physicochemical properties of 
the drug, the composition of the drug formulation and physiological composition of the 
membrane barrier will determine whether CDs will enhance or hamper drug delivery through 
biological membranes. Most biological membrane barriers are lipophilic with an aqueous 
exterior, which forms a structured water layer at the membrane surface frequently referred to 
as unstirred diffusion layer. If drug permeation through the aqueous diffusion layer is the 
rate–limiting step of drug permeation through the barrier, CDs can frequently enhance the 
permeation [7]. 
CD lowers permeability and raises solubility, but the two effects are most often not 
equal in magnitude [68]. CDs can enhance the aqueous solubility of lipophilic drugs without 
changing their intrinsic ability to permeate biological membranes. Thus, through CD 
complexation it is possible to move BCS Class II drugs, and sometimes even Class IV drugs, 
into Class I. However, CDs can decrease BA of Class I drugs and will in most cases not 
improve BA of Class III drugs. In general CDs enhance drug delivery through biomembranes 
by increasing the drug availability at the membrane surface. At the surface the drug molecules 
partition from the CD cavity into the lipophilic membrane. Thus, properly designed CD 
formulation will increase the drug concentration gradient over the membrane, which will 
increase the drug flux through the membrane. Since drug/CD complexes do not readily 
permeate biomembranes, excess CD in pharmaceutical formulations can reduce drug BA. 
Including CDs in pharmaceutical formulations will however increase the formulation bulk of 
solid dosage forms. Even under best conditions, CD complexation will result in 4 – 10–fold 
increase in the formulation bulk. This limits the use of CDs in solid oral dosage forms to 
potent drugs that possess good complexing properties. [69]. 
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3.4. Application of CDs in pharmaceutics 
 
In Fig. 4 there are introduced the diversified availabilities of CDs with some examples. 
 
 
Fig. 4 Application fields of CDs [70] 
 
CDs applications in drug delivery are the followings: oral, parenteral, ocular, nasal, 
rectal, controlled, colon–specific, peptide and protein, gene and oligonucleotide, dermal and 
transdermal, brain targeting, liposomes, microspheres, microcapsules, nanoparticles [71]. 
Worldwide about 40 different pharmaceutical products containing CDs are on the market, 
which are summarized in Table 4. 
If a poly–α–amino acid chain is combined with β–CD, a new amphiphilic completely 
biodegradable polymer can be afforded. Both biodegradability and amphiphilicity are 
extremely significant properties for some applications of biomedical polymers. The 
amphiphilic biodegradable polymers may be used as controlled release of drugs [72]. 
HPBCD and Captisol are typically used in formulation for preclinical studies [73]. 
A.G. Ellis et al. used Captisol for making an aqueous formulation with appropriately high 
concentration for the assessment of tissue distribution and pharmacokinetic studies of the 
active ingredient [74]. 
C.E. de Matos Jensen et al. showed that β-CD improved the solubility and BA of 
valsartan, because the complex reduced the arterial blood pressure much better than valsartan 
alone in in vivo rat experiments [75]. Besides hundreds of article can be found in the literature 
in that solubility was improved by CDs. 
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Table 4 CD containing pharmaceutical products [76, 77] 
Drug Trade name Formulation Company 
α–CD 
Alprostadil (PGE1) 
Prostavasin 
Caverject Dual 
Edex 
iv. solution and 
infusion 
Ono, Schwarz 
Pfizer 
Limaprost (OP-1206) Opalmon, Prorenal tablet Ono 
Cefotiam–hexetil HCl Pansporin T tablet Takeda 
β–CD 
Benexate HCl Ulgut Lonmiel capsule 
Teikoku 
Shionogi 
Cephalosporin Meiact tablet Meiji Seika 
Cetirizine Cetrizin chewing tablet Losan Pharma 
Chlordiazepoxide Transillium tablet Gador 
Dexamethasone Glymesason ointment, tablet Fujinaga 
Dextromethorphan Rynathisol tablet Synthelabo 
Diphenhydramine HCl, 
chlortheophylline Stada–Travel chewing tablet Stada 
Iodine Mena–Gargle solution Kyushin 
Meloxicam Mobitil tablet and suppository Medical Union Pharmaceuticals 
Nicotine Nicorette sublingual tablet Pfizer 
Nimesulide Nimedex tablet Novartis 
Nitroglycerin Nitropen sublingual tablet Nihon Kayaku 
Omeprazole Omebeta tablet Betafarm 
PGE2 Prostarmon E sublingual tablet Ono 
Piroxicam 
Brexin 
Flogene 
Cicladol 
tablet, suppository, 
liquid 
Chiesi 
Aché 
Tiaprofenic acid Surgamyl tablet Roussel-Maestrelli 
2–hydroxy–propyl–β–CD (HP–β–CD) 
Cisapride Propulsid suppository Janssen 
Hydrocortisone Dexocort solution Actavis 
Indomethacin Indocid eye drop solution Chauvin 
Itraconazole Sporanox oral and iv. solutions Janssen 
Mitomycin Mitozytrex, MitoExtra iv. infusion Novartis 
Random methylated β–CD (RMBCD) 
Chloramphenicol Clorocil eye drop solution Oftalder 
17–β–estradiol Aerodiol nasal spray Servier 
Sulphobuthylether–β–CD (Captisol) 
Aripiprazole Abilify im. solution Bristol Myers Squibb, Otsuka Pharm. 
Maropitant Cerenia sc. solution Pfizer Animal Health 
Voriconazole Vfend iv. solution Pfizer 
Ziprasidone mesylate Zeldox Geodon im. solution Pfizer 
2–hydroxy–propyl–γ–CD (HP–γ–CD) 
Diclofenac Na Voltaren 
ophtha eye drop solution Novartis 
Tc–99 Teoboroxime CardioTec iv. solution Bracco 
The products with bold Roman type are marketed in Hungary, too. 
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3.5. Application of CDs beyond pharmaceutics 
 
β–CD is used in food industry for removing cholesterol from cream [78], reduction of 
undesired taste, extension of food products shelf life [79]. Y.Q. Tian et al. demonstrated that 
β–CD has significant impact on the staling of crust and cumb. The retarding effect of β–CD 
was strongly supported by the less changes of hardness, cohesiveness and springiness [80]. 
CDs play role in enzyme mimicking, chiral chromatographic separations and a new 
applicability is that β–CD is a template in a biomimetic synthesis of spherical hydroxyapatite 
crystals [81]. 
CD complexation represents a unique and effective strategy for improving the protein 
therapy by stabilizing them against aggregation, thermal denaturation and degradation [82]. 
CDs improve the steroids biotransformation. M. Wang et al. represented that HP–β–
CD enhances the 1–en–dehydrogenation of cortisone–acetate catalyzed by a microorganism. 
It not only increases the reaction rate but also improves the final substrate conversion rate 
[83]. 
It was possible to form inclusion complexes between the CDs and metal ions like Pb2+. 
The β–CD and its derivatives have been used for the removal of polluting species from 
wastewater. The use of water–insoluble β–CD immobilized on polymeric matrices or solid 
supports has led to the development of novel decontaminating agents [84]. 
The self–assembles monolayers of thiolated CD derivatives has constructed on the 
surface of Au electrodes, producing a modified electrode selective towards electrochemical 
reactions characterized by cyclic voltammetry. This modified electrode is an environmentally 
friendly alternative to substitute the hanging mercury drop electrode [84]. 
The separation of structural isomers can be achieved by using β–CD thanks to 
inclusion complex formation which depends on size and polarity of the host molecule and its 
shape. β–CD has been used as a mobile phase component in reversed–phase HPLC and also 
in stationary phases, both in liquid and gas chromatography [85]. 
Some researchers have shown the efficiency of CDs for PAH (polycyclic aromatic 
hydrocarbons) removal from soils by aqueous washing [86, 87]. 
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4. Loratadine (LOR) 
 
Chemical name: ethyl–4–(8–chloro–5,6–dihydro–11H–benzo[5,6]cyclohepta[1,2–b]pyridin–
11–ylidene)–1–piperidinecarboxylate 
Chemical structure (see Fig. 5): 
 
Fig. 5 Chemical structure of LOR 
 
Molecular formula: C22H23ClN2O2 
Mw: 382.89 
Melting point: 132 – 135 ˚C 
Description: white or off–white crystals or powder [88] 
Trade names: Clarinase®, Claritine®, Claritine akut®, Erolin®, Flonidan®, Lorano®, 
                       Loratadin Hexal®, Loratadin–ratiopharm®, Roletra® 
  
LOR is a tricyclic, piperidine derivative of antihistamines. It belongs to the second 
generation antihistamines, so it has non–sedating properties. H1 antihistamines are applied in 
the treatment of allergies: they prevent symptoms such as itching, congestion, rhinorrhoea, 
tearing and sneezing [89]. 
LOR belongs to Class II of the BCS [90]. LOR is a weak base; its pKa value at 25 °C 
has been reported as 4.85 – 6.00 [89–92]. The solubility of bases increases with decreasing 
pH at pH values less than the pKa [9]. At lower pH values, LOR – which is a nitrogen base – 
is protonated, and therefore becomes more soluble in water [91]. However according to the 
modified Hendersson–Hasselbach equation [93], at ~ pH 7 and higher LOR is totally 
unionized, which is the form able to absorb, so LOR will probably absorb from the intestines, 
in which it has poor solubility. 
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It is metabolized by the cytochrom P450 to an active metabolite, desLOR, which is 
153 times more potent than LOR. The presumed reason for this notable affinity difference is 
that LOR’s amine group cannot interact with the carboxylate part of the receptor (Asp 107) 
since it is not protonated in physiological pH. DesLOR does not have the electrophilic ethyl–
ester group which reduces the basicity of the molecule, so desLOR has pKa value at 8.65, the 
amine group can be protonated at physiological pH [94]. It has a very big affinity to the 
plasma proteins (~98%). The defined daily dose of LOR is 10 mg [95]. LOR is a substrate for 
the P-gp. P-gp is an ATP–dependent efflux transporter that affects the absorption, distribution 
and excretion of compounds [96]. Increased intestinal expression of P-gp can reduce the 
absorption of drugs that are substrates for P-gp. Thus, there is a reduced BA, therapeutic 
plasma concentrations are not attained [97]. 
LOR is official in the undermentioned pharmacopoeias: British Pharmacopoeia 2012 
[57], The United States Pharmacopoeia 34 – National Formulary 29 [58], European 
Pharmacopoeia 7.4 [59]. 
 
 
5. Materials and methods 
 
 
5.1. Materials 
 
α–CD, β–CD, γ–CD, randomly methylated–β–CD (RAMEB), 2–hydroxypropyl–β–CD 
(HPBCD), methyl–β–CD, hydroxy–butyl–β–CD and heptakis–(2,6–di–O–methyl)–β–
cyclodextrin (DIMEB) were purchased from Cyclolab Ltd. (Budapest, Hungary), β–CD–
sulfobutyl–ether (Captisol) originated from CyDex Pharmaceuticals Inc. (Lenexa, USA). 
LOR (ethyl 4–(8–chloro–5,6–dihydro–11H–benzo–[5,6]–cyclohepta[1,2–b]pyridin–11–
ylidine)–1–piperidine–carbo–xylate) was kindly provided by TEVA Pharmaceutical 
Industries Ltd. (Hungary). Compound 48/80 (N-methyl-4-methoxy-phenethylamine) was 
supplied by Sigma-Aldrich Logistic GmbH, Germany. Other chemicals were of analytical 
reagent grade purity. 
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5.2. Methods 
 
5.2.1. Preliminary experiments 
The effects of the various CD derivatives on the solubility of LOR were investigated at 25 ºC. 
20 mg of LOR and 200 mg of the CD derivatives were suspended in 20 mL of distilled water. 
The mixture was stirred at 10 min with a magnetic stirrer and then filtered, and after suitable 
dilution the UV spectrum was recorded in the range 220–300 nm. 
 
5.2.2. Phase solubility studies 
The phase–solubility diagrams were recorded by the Higuchi–Connors method [8]. For this 
purpose aqueous solutions of CDs of various concentrations were prepared at a specific pH 
value (7.5) (250 mL of 0.2M KH2PO4, 204 mL of 0.1 M NaOH made up to 1000 mL with 
distilled water). An excess amount of LOR was added to these solutions, and they were then 
shaken at room temperature. After 72 h, the suspensions were filtered through 0.45 µm 
membrane filters. After dilution, their absorption was measured by UV spectrophotometry 
(λ = 248 nm). The presence of the CD did not disturb the spectrophotometric assay. Each 
experiment was performed in triplicate. 
 
5.2.3. Preparation of products 
DIMEB proved to demonstrate the best enhancement of the solubility (see section 6.1). The 
products were prepared in three molar ratios (LOR:DIMEB = 1:1, 1:2 and 1:3) by four 
methods: physical mixing, kneading (two different methods for removing the solvent) and 
spray–drying. Physical mixtures (PMs): LOR was mixed carefully in a mortar with the 
calculated amount of CD. Kneaded products (KPs): the physical mixtures were suspended 
with the same mass of 50% ethanol, and the solvent was evaporated off at room temperature. 
After drying, the products were ground. Microwave products (MWs): the preparation is the 
same with kneaded products to the end of suspension step. Then the evaporation of the 
solvent was carried out in a MW oven (Milestone Ethos TC MW apparatus, Advanced 
Microwave Labstation, Italy). The method of MW treatment was as follows: 150 W, 90 s, 
60 °C, and the samples were then dried under vacuum [98]. Spray–dried products (SDs): the 
physical mixtures were dissolved in 50% ethanol, and SDs were obtained by using a Büchi 
Mini Spray Dryer B–191 (BÜCHI Labortechnik AG, Flawil, Switzerland), at an inlet 
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temperature of 105 oC, with a compressed air flow of 800 L/h and a nozzle diameter of 
0.5 mm. The aspirator rate was 75–80%, and the pump rate was 5–10%. All of the samples 
were sieved (100 µm) and stored at room temperature under normal conditions. 
The solid dispersions of LOR in PVP K-25 containing four different ratios (1:1, 1:2, 1:4 and 
1:6 w/w) were prepared by the solvent evaporation method (SEs). LOR and PVP K-25 were 
dissolved in methanol and the solvent was removed by vacuum dryer during 6 hours. All of 
the products were pulverized in a mortar and sieved through a 100 µm sieve. 
 
5.2.4. In vitro dissolution studies 
The modified paddle method with the USP dissolution apparatus (Erweka Type DT, 
Germany) was used to examine 200 mg samples of pure LOR or products containing 200 mg 
of LOR in 100 mL of simulated gastric medium (SGM) (pH = 1.1 ± 0.1; 94.00 g of 1 M HCl, 
0.35 g of NaCl, and 0.50 g of glycine made up to 1000 mL with distilled water) or simulated 
intestinal medium (SIM) (pH= 7.0 ± 0.1; 14.4 g of Na2HPO4·2H2O and 7.1 g of KH2PO4 
made up to 1000 mL with distilled water). The paddle was rotated at 100 rpm and sampling 
was performed up to 120 min (sample volume 5.0 mL). Aliquots were withdrawn at 5, 10, 15, 
30, 60, 90 and 120 min and immediately filtered. At each sampling time, an equal volume of 
fresh media was added, and the correction for the cumulative dilution was calculated. After 
filtration and dilution, the LOR contents of the samples were determined 
spectrophotometrically (λSGM = 276 nm, λSIM = 248 nm). 
 
5.2.5. Study the effect of pH on the solubility 
Seven buffer solutions were prepared with different pH values between 1.2 and 7.5 [11]. The 
defined daily dose of LOR is 10 mg, so 10 mg of LOR or product containing 10 mg of LOR 
was examined in 900 mL of dissolution media at 37 °C. The paddle was rotated at 100 rpm. 
After 2 h the removed samples were filtered and the LOR concentrations were measured 
spectrophotometrically. 
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5.2.6. Thermoanalytical measurements 
 
5.2.6.1. DSC 
The DSC records were obtained with a Mettler Toledo DSC 821e (Mettler Inc., 
Schwerzenbach, Switzerland) apparatus. Between 2 and 5 mg of sample was measured in a 
standard aluminium pan (40 µL) and heated from 25 to 300 °C at a heating rate of 5 °C/min 
under a constant purge of argon at 10 L/h. 
 
5.2.6.2. Thermogravimetric measurements 
The TG, DTG and DTA curves were recorded in parallel in platinum crucibles with the same 
thermal program (heating range 25–300 °C, heating rate 5 °C/min), using a MOM 
Derivatograph–C (MOM Co., Hungary). The reference was a crucible containing aluminium 
oxide. 
 
5.2.7. FT–IR 
Samples with a LOR content of 0.5 mg were ground and mixed with 150 mg of dry KBr in an 
agate mortar, and the mixture was then compressed into a disc at 10 t. Each disc was scanned 
64 times at a resolution of 4 cm–1 over the wave number region 4000–400 cm–1 with an FT–
IR spectrometer (Thermo Nicolet AVATAR 330, USA). The evaluation was carried out with 
the GRAMS/AI Ver. 7 program. 
 
5.2.8. ESI–MS 
The compounds were characterized by MS, using a Finnigan MAT 95S sector field mass 
spectrometer equipped with an electrospray ion source. Positive-ion ESI-MS spectra were 
obtained. The solutions were prepared in a 1:1 mixture of acetonitrile/water. The solutions 
were infused directly into the mass spectrometer at a rate of 200 µL/min. Data were collected 
for approximately 100 scans. The scan range was 100-3000 m/z. The spectrometer was used 
at a resolution of ~ 1000–1500. 
 
5.2.9. DOSY 
Diffusion coefficients (D) were estimated via DOSY NMR experiments. In the DOSY 
spectra, chemical shifts were located along the F2 axis and D values along the F1 axis. From 
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the D values, it is possible to infer the size of the species and therefore the absolute 
stoichiometry of the supramolecular complexes. 
The NMR spectra were recorded at 25 ºC on a Bruker Avance DRX 400 MHz spectrometer. 
For 2D DOSY 1H NMR, pulsed field-gradient spin-echo NMR measurements were performed 
by using the stimulated echo and longitudinal eddy current delay (LED) sequence [99]. A 
time of 1.5 ms was used for the dephasing/refocusing gradient pulse length (δ), and 100 ms 
for the diffusion delay (∆). The gradient strength was changed quadratically from 5% to 95% 
of the maximum value (B-AFPA 10 A gradient amplifier), and the number of steps was 16. 
Each measurement was run with 32 scans and 16K time domain points. For the processing, an 
exponential window function and single zero filling were applied. During the diffusion 
measurements, the fluctuation of the temperature was less than 0.1 K. Prior to the NMR 
scans, all the samples were equilibrated for 30 min. The data were analysed by using 
XWINNMR 2.5 software. 
 
5.2.10. PAMPA 
PAMPA “sandwiches” (Fig. 6) were formed from an acceptor 96-well microtitre plate 
(Millipore MATRNPS 50) and a matching filter plate (Millipore Multiscreen®-IP, MAIPNTR 
10) with apparent porosity of 0.45 µm, coated with 5 µL of 1 w/v% n-dodecane solution of 
lecithin. The initial donor sample concentrations were about 150 µM. The plate sandwich was 
allowed to incubate at 25±1 °C for 16 hours without stirring, in an atmosphere saturated in 
humidity. Afterwards, sample concentrations in both the acceptor and donor wells were 
determined by HPLC method. Effective permeability coefficients, Pe, were determined by 
taking into account the apparent filter porosity and sample mass balance. 
The donor (VD=150 µL) and acceptor (VA=300 µL) compartments were both constituted of 
pH 7.4 buffer solutions. 
The permeability rates were calculated using by the equation (Equation 2.) below: 
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Fig. 6 Schematic structure of the PAMPA model [100] 
 
5.2.11. In vivo experiments 
This study was approved by the Committee on Animal Research at the University of Szeged 
(IV./01758-6/2008). A colony of inbred 150 ± 5 g male Wistar rats (Charles River 
Laboratories, Germany) was used, fed commercial rodent pellets and tap water. The animals 
were housed in groups of 5 at a controlled room temperature (22 ± 1 ºC) and maintained 
under an alternating 12 h light/12 h dark cycle (light on at 6:00 am). 
The following materials were tested in this study: LOR, DIMEB, KP 1:1 and KP 1:2 
(LOR:DIMEB). The test substances were given orally in suspension in 0.25% methylcellulose 
in a dose of 10 mg/kg (1.00 mL/kg). The animals were divided into five groups, with 6 rats 
per group. Group I received the vehicle and served as a control. To study the influence of 
DIMEB on the oedema, the Group II animals received DIMEB. LOR, KP 1:1 and KP 1:2 
were administered to the other three groups, respectively. 
In these experiments, at first the animals were treated orally by the above mentioned 
suspensions. 1 h later the histamine liberator compound 48/80 in physiological solution 
(10 µg/0.1 mL) was administered subplantarly to elicit the inflammatory reaction [101, 102]. 
In light isoflurane narcosis the intensity of the arising inflammatory reaction was measured 
after 30 min with the use of a plethysmometer (Ugo Basile, Harvard Apparatus, Germany) on 
the basis of the volume difference between the right hind leg treated with compound 48/80 
and the left hind leg treated with vehicle (physiological saline). Immediately after measuring 
the extent of the oedema, blood samples were taken from rats by cardiac puncture and 
collected in tubes containing sodium-EDTA. Then these samples were centrifuged and the 
obtained plasmas were frozen until the measurement of LOR-content (see below). 
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A high-performance liquid chromatographic (HPLC) method has been developed for 
quantitative analyses of LOR in in vitro (PAMPA model) and in vivo samples. HPLC 
measurements were performed with a JASCO PU-1580 binary pump (JASCO Inc., Japan) and 
a programmable variable UV-visible detector. LOR was chromatographed on a 
100 mm × 4.6 mm i.d., 3 µm particle, Phenomenex Luna C8(2), 100 Å analytical column 
under reversed-phase conditions at 30 ºC, protected with a SecurityGuard Cartridge 
(4.0 mm ×  2.0mm) pre-column. The degassed mobile phase was a 47:42:11 (v/v) mixture of 
acetonitrile, purified water and a phosphate buffer solution (0.5 M, pH 3.0 ± 0.1, adjusted by 
the addition of 85% orthophosphoric acid). The flow rate was 1.0 ml/min and the analyte was 
monitored at 250 nm. 
Calibration plots were constructed by analysis of working solutions (concentrations of 5, 10, 
25, 50 and 75 µg/mL (in vitro) and 5, 10, 50, 75 and 100 ng/mL (in vivo)) of LOR in the 
mobile phase and plotting concentration against peak-area response for each injection. The 
calibration curves were linear throughout the whole range tested and described by the 
equations y = 20.318 · x – 23,775 (R2 = 0.9912) and y = 1083.4 · x + 31.777 (R2 = 0.9957) 
for the in vitro and in vivo measurements, respectively. Unknown samples were quantified by 
reference to these calibration plots. Inter-day precision was calculated from results on the 
calibration sample of 5 µg/mL analysed on 20 consecutive days (n = 5). The mean amount 
found was 4.98 µg/mL and the RSD value was 2.47%. The limits of detection (LOD) and 
quantification (LOQ) were determined on the basis of the S.D. of the response (y-intercept) 
and the slope of the calibration plot. LOD and LOQ for LOR were 0.004 and 0.013 µg/mL, 
respectively. 
500 µL of mobile phase was added to 500 µL of plasma, and this mixture was then 
centrifuged at 17 000 rpm for 15 min. The clear supernatant was next collected and filtered 
through a 0.22 µm membrane filter (Millipore). From this solution, a 100 µL aliquot was 
injected for HPLC analysis. 
Statistical analyses were performed with Prism 4.0 software (GraphPad, San Diego, CA, 
USA). Differences in paw oedema between the treatment and control groups were determined 
by one-way analysis of variance (ANOVA) with the Newman-Keuls post hoc test. The 
criterion for statistical significance was taken as p < 0.05. An experimental group contained 
6 rats. All values are expressed as mean ± S.E. 
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6. Results 
 
6.1. Preliminary studies 
 
The results were compared with the data of the CD–free system (see Table 5). The best 
solubility enhancement was achieved with DIMEB, which resulted in an approximately 300–
fold increase in solubility, and accordingly this derivative was used in the further 
examinations.  
 
Table 5 Effect of CD derivatives on solubility enhancement (25 ºC) 
 c (µg/mL) solubility enhancement (–fold) 
LOR 2.43 1.00 
+ α–CD 23.69 9.75 
+ γ–CD 34.73 14.29 
+ Captisola 80.05 32.94 
+ HP–β–CDb 128.14 52.73 
+ H–Bu–β–CDc 181.69 74.77 
+ β–CD 212.02 87.25 
+ RAMEBd 496.89 204.48 
+ Me–β–CDe 592.62 243.88 
+ DIMEB 730.87 300.77 
 
a
 sulphobuthylether–β–CD 
b 2–hydroxypropyl–β–CD 
c hydroxybuthyl–β–CD 
d random methylated–β–CD 
e methyl–β–CD 
 
6.2. Phase–solubility studies 
 
A relevant diagram is shown in Fig. 7, the solid line indicates the best linear regression fit of 
the experimental data. Higuchi and Connors [8, 55] defined 2 main types of diagrams. In 
general, type A diagram describes the characteristics of the water–soluble CD derivatives, 
while type B illustrates the properties of the less–soluble natural CDs. In the case of type A, 
the solubility of the drug raises with the increase of CD concentration. B–type phase–
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solubility profiles reflect the formation of complexes with limited solubility in aqueous 
medium. Type A has 3 subtypes (AN, AL and AP). The subtype of the present diagram is AL. 
The most common type of CD complexes is the 1:1 drug:CD complex. The most common 
assumption is that a slope of less than 1 for a type AL diagram indicates the formation of a 1:1 
complex. The stability constant (K1:1) of the complex can be calculated from the slope and the 
intrinsic solubility of the drug in the aqueous medium (Equation 3). In the absence of 
DIMEB, the equilibrium water solubility of LOR (S0) was determined to be 0.81 ± 0.14 mg/L. 
The K1:1 value of LOR:CD complex is very large: 1.48 x 106 M–1. The linear regression 
coefficient (R2) is 0.9991. 
 
)1(01:1 slopeS
slopeK
−
=                                                                                                                         Equation 3. 
 
 
Fig. 7 Phase–solubility diagram of LOR and DIMEB 
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6.3. In vitro dissolution studies 
 
According to the pKa value the solubility of LOR depends on the pH: LOR can undergo 
protonation on the N of the pyridine ring in acidic media, forming salts with good solubility, 
so it exhibits good dissolution in acidic medium (e.g. SGM), but dissolves poorly in alkaline 
medium (e.g. SIM). The presence of DIMEB did not alter the solubility of LOR in SGM: the 
total investigated amount of the sample was dissolved in the first 5–10 min, independently 
from the preparation method and the composition. Concerning to the dissolution of DIMEB 
products in SIM, the rate of dissolution was improved for all of the products, but the extent of 
this increase depended on the preparation method and the molar ratio. For the 1:1 
compositions (Fig. 8), none of the preparation methods resulted in 100% dissolution. The 
lowest solubility enhancement was observed for the PM (8.7–fold), as expected, as this mode 
of preparation did not result in a complex generally. The KP and MW furnished similar 
solubility increase (67.6– and 71.5–fold). However the best enhancement was achieved with 
the SD (142.9–fold). For the 1:2 and 1:3 preparations (Fig. 9 and Fig. 10) the PM displayed 
similar results as for the 1:1 product, with only a slight further improvement in solubility 
(10.26– and 13.7–fold, respectively). For the KP, MW, SD 1:2 and 1:3 products, the whole of 
the investigated samples dissolved in the first 15 min, i.e. the dissolution in SIM was as good 
as in SGM. This means that the same good dissolution can be obtained at the extreme pH 
values of the gastrointestinal tract with the use of these DIMEB products. Accordingly, if the 
rate–limiting step of absorption was not the dissolution, the permeability would regulate the 
passage through the membrane. As LOR has good permeability, the application of LOR 
complexed with a CD such as DIMEB would lead to a greater quantity of drug being 
absorbed, so that better BA would be obtained. 
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Fig. 8 Dissolution of LOR and 1:1 products in SIM 
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Fig. 9 Dissolution of LOR and 1:2 products in SIM 
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Fig. 10 Dissolution of LOR and 1:3 products in SIM 
 
However LOR SEs did not give much better result in SIM (Fig. 11). The dissolution did not 
change in SIM, where 1:1 and 1:2 ratios showed worse dissolution compared to the raw drug. 
In the case of 1:4 and 1:6 product the initial appearance of increased dissolution rate can be 
explained by the faster dissolution of the amorphous drug and after the rapid dissolution the 
API recrystallizes. As the SEs did not improve the solubility and dissolution rate of LOR 
adequately, they were not tested in the further studies. 
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Fig. 11 Dissolution of LOR and SE products in SIM 
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6.4. Study the effect of the pH on the solubility 
 
The defined daily dose of LOR is 10 mg. The solubility of LOR has been reported to decrease 
with increasing pH [90]. As can be seen in Fig 12 and 13, the applied dose of pure LOR did 
not dissolve at the pH of intestines, from where it is absorbed. In the acidic range (up to 
pH ~3) both the 1:1 and 1:2 compositions can provide that the applied dose is dissolved. 
However with the increasing pH, DIMEB is not able to dissolve the whole quantity, so the 
BA will not be good enough. According to the dissolution results, PM shows worse 
dissolution, than KP and SD. By the PM 1:2 product the result is similar to the previous one. 
In contrast, virtually the whole quantity of LOR dissolved from the KP and SD 1:2 products 
both in the acidic and alkaline media, so the solubility of LOR became independent of the pH. 
This clearly suggests an opportunity to ensure smooth dissolution for LOR, thereby achieving 
better and more uniform BA. In case of the 1:3 products it can be stated the same as by the 1:2 
products. 
As the SEs did not improve the solubility and dissolution rate of LOR adequately, they were 
not tested in this study. 
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Fig. 12 pH–dependence of the solubility of LOR and 1:1 products 
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Fig. 13 pH–dependence of the solubility of LOR and 1:2 products 
 
 
6.5. Results of thermal analysis 
 
DSC thermograms of LOR and its products are shown in Fig. 14-17. The sharp, 
narrow endothermic peak in the DSC spectrum of LOR (peak 133.16 oC, normalized melting 
enthalpy 89.48 J/g) denotes the melting point of the material. The stability of LOR was not 
affected (no degradation was observed) up to 300 oC. Our DIMEB was amorphous, and there 
was no thermoanalytical indication at the melting point of LOR, however there was an 
exothermic peak reflecting the recrystallization of DIMEB at 181 oC (loss in mass was not 
detected in the TG curve). Above 320 oC, a broad endothermic peak was observed, associated 
with decomposition of the material. 
LOR has no moisture content, as concluded from the TG curve. The moisture content 
of DIMEB is less than 0.5%, as determined from the TG curve and traditional gravimetry 
after drying in a drying chamber. The moisture contents of the products were also very low, 
there was no broad endothermic peak under 100 oC (representing the water content). 
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Fig. 14 DSC curves of 1:1 products 
 
The results of the 1:1 compositions are presented in Fig. 14. For the PM, the melting 
point of LOR was seen several degrees lower than of pure LOR (this is characteristic for CD 
complexes) and the area under the peak was quite proportional to the amount of LOR in the 
sample. Hence, total inclusion complexes were not formed in the PM product. For the KP and 
SD samples, no endotherm reflected the melting point of LOR. For the MW and SD samples 
it is possible that the product becomes amorphous during the preparation method or that total 
complexation is occurred. For the KPs, similar phenomena could be observed, although there 
is no possibility for amorphization during the slow drying, accordingly total complexes were 
formed. 
In case of all the 1:2 and 1:3 products similar conclusion can be drawn (as shown in 
Fig. 15 and 16). The PM method did not result in total inclusion complexation. KPs effected 
total inclusion complexes, MWs and SDs can be amorphous or inclusion complexes. To 
answer this question, further investigations were performed (FT-IR). 
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Fig. 15 DSC curves of 1:2 products 
 
               
Fig. 16 DSC curves of 1:3 products 
 
For these products the exotherm due to DIMEB was observed to have moved to lower 
temperature (about 170 oC). This phenomenon was seen for both KPs and MWs, and it can be 
stated consequently that applying the MW power did not cause changes in the chemical 
structure of the LOR molecule. 
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For the PMs the presumed uncomplexed guest (active material) percentages were 
estimated semiquantitatively from the DSC curves by using the following equation 
(Equation 4.): 
 
4
0
10×
×∆
∆
=
cH
H
c iun            Equation 4. 
 
where cun is the uncomplexed guest %; ∆Hi is the normalized integral value for the product; 
∆Ho is the normalized integral value for the active ingredient; and c is the percentage of active 
ingredient in the product. Table 6 presents the results for the different compositions. 
 
Table 6 LOR + DIMEB PMs complex ratio 
 Uncomplexed LOR % 
1:1 40,8 
1:2 22,9 
1:3 27,7 
 
Based on these results it can be stated that the PM products are partial complexes. 
 
In the case of SEs the DSC curves (Fig. 17) represented no melting point of the drug, 
except the 1:1 product, where a little shifted endotherm peak appeared at around 133 oC. Due 
to the preparation method it is expectable to forming an amorphous product which was proved 
by X-ray powder diffractometry (data not shown). However the 1:1 composition contained a 
small crystalline phase, as well. 
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Fig. 17 DSC curves of LOR, PVP K-25 and SE products 
 
6.6. FT–IR examinations 
 
The spectral changes were evaluated by subtraction of the spectrum of DIMEB from 
the spectra of the samples. The spectra of the products involving different molar ratios and 
preparation methods did not differ appreciably. 
The FT–IR spectra of LOR show the presence of the following peaks: 2983 cm–1 
(aromatic C–H stretching), 2883 cm–1 (aliphatic C–H stretching), 1703 cm–1 (C=O stretching), 
1580 and 1560 cm–1 (C=C stretching), 1474 and 1323 cm–1 (aliphatic C–H blending), 1435 
cm–1 (C=N stretching), 1227 cm–1 (C–O stretching), 1117 cm–1 (C–Cl stretching), 831 and 
764 cm–1 (aromatic C–H blending) and the FT–IR spectra of DIMEB showed prominent 
absorption bands at 3424 cm–1 (for O–H stretching vibrations), 2930 cm–1 (for C–H stretching 
vibrations) and 1159 cm–1, 1086 cm–1 (C–H, C–O stretching vibration). 
The difference spectra of the PM products were practically identical to the spectrum of 
pure LOR, indicating negligible interaction between LOR and DIMEB. For the KP, MW and 
SD samples (see Fig. 18–20), the characteristic C=O stretching frequency (1702 cm–1) was 
shifted to lower wave numbers, and the typical C–O stretching at 1227 cm–1 was shifted to 
higher range. These results lead us to assume that the –COO group provides the complex–
forming bonds to the outer surface of DIMEB and that complex formation alters the 
hydrogen–bonded cyclic dimeric structure involving the carboxyl group. During the formation 
of the inclusion complex, hydrogen–bonds develop between LOR and DIMEB, and the 
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inclusion complex can therefore be regarded as co–crystals [103]. A lipophilic part of LOR 
will probably be attached to the inner surface of DIMEB, like the aromatic rings, but in the 
FT–IR spectrum of LOR, the characteristic stretching frequencies of these aromatic parts are 
masked by DIMEB, so these interactions can not be detected with this method. 
 
                 
Fig. 18 FT-IR difference spectra of LOR and 1:1 products 
 
                 
Fig. 19 FT-IR difference spectra of LOR and 1:2 products 
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Fig. 20 FT-IR difference spectra of LOR and 1:3 products 
 
In accordance with the DSC finding, in the KP products, total complexation occurred, 
and FT–IR also revealed total complexation for the MW and SD samples. 
 Based on the dissolution, the DSC and FT-IR results it was found that the applied 
microwave power did not cause any chemical changes in the molecule of LOR, the KP and 
MW products possess the same characteristic, therefore only one (the KP) of these 
preparations was investigated in the following studies. 
 On the FT-IR spectra of LOR SEs (data not shown) strong interaction can be seen 
between LOR and PVP. The PVP presents an apolar medium for LOR, and as LOR is a 
lipophilic drug, it rather likes to stay in an apolar medium, than to go to the hydrophilic, 
aqueous medium. As the SE products were not suitable of our aims (did not enhance the 
dissolution of LOR), other studies were not carried out with these products. 
 
6.7. ESI–MS 
 
ESI-MS is the most promising tool for the characterization of different kinds of host-
guest complexes in the gas phase [104]. It can provide evidence of complexation and 
stoichiometry on the basis of the molecular weights of all vaporized species. The study of 
host-guest interactions in the gas phase allows the detection of specific interactions not 
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necessarily present in solution, thereby giving a complementary picture of the intrinsic 
phenomena responsible for molecular recognition. Also, there are interpretation ambiguities 
as concerns the ESI-MS spectra of supramolecular assemblies, e.g. deciding whether the 
species present in the mass spectra correspond to those present in solution, or they rather 
result from processes occurring under high-vacuum conditions. Moreover, it is not clear 
whether the molecular ions observed are real inclusion complexes or only ion-dipole external 
adducts, i.e. „false positives” [105]. In our particular case, however, a comparison can easily 
be made with the aid of results obtained from independent solution-phase techniques. 
The hydroxyl groups of CDs are not easily protonated or deprotonated; ESI-MS 
analyses are usually carried out in the presence of salts in order to enhance detection. 
The positive ESI spectra of KP 1:1 and KP 1:2 are reported in Fig. 21 and Fig. 22, 
respectively. 
An interesting feature of the ESI-MS binding of the analytes with the CDs is the 
reproducible loss of water. This water loss is presumed to arise from displacement of water 
from the CD cavity. 
Host-guest complexes formed in solution are also stable for characterization by ESI in 
the gas phase. 
The ESI of DIMEB with positive ion detection leads to a series of protonated 
molecules, [M+H]+, at m/z values depending on the number of methyl groups in each 
individual sugar unit of the CD derivative. The mass spectra reflect the average distribution of 
the methyl groups of DIMEB. It should be noted that the ion peak at m/z 1331 corresponds to 
14 O-methyl groups (i.e. heptakis(2,6-di-O-methyl)cyclomaltoheptaose to a first 
approximation) [106]. 
As expected, the spectrum essentially involved peaks due to singly charged ions of 
pure LOR [at m/z 383 as (LOR)H+] and pure DIMEB [at m/z 1331 as (DIMEB)H+]. A new 
signal corresponding to the inclusion complex as a singly charged ion (DIMEB+LOR)H+ is 
observed at m/z 1730. 
While the mixtures with different molar ratios (1:1 or 1:2) of LOR and DIMEB were 
analysed by ESI-MS, only the 1:1 complex was found in all the mass spectra, which suggests 
that the DIMEB inclusion complex in the gas phase has a certain stoichiometry. 
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           Fig. 21 ESI-MS spectra of KP 1:1        Fig. 22 ESI-MS spectra of KP 1:2 
 
6.8. DOSY 
The D value observed in the NMR experiment (fast-exchange condition) is the 
weighted average of those of the bound and the free guest. The rationale behind the extraction 
of the bound fraction from diffusion NMR measurements is simple. The host and guest have 
their own D values in the free state, reflecting their molecular weight and shape. The guest 
molecules are significantly smaller than CD, and the D values of the bound guests were taken 
to be equal to that of CD; it was assumed that, for the binding of a small guest molecule to a 
large host molecule, the D value of the host is not greatly perturbed and that of the host-guest 
complex can be assumed to be the same as that of the non-complexed host molecule. In the 
case of a weak or negligible association, the D values of the host and the guest will remain 
unchanged. For any other case, assuming fast exchange on the NMR time scale, the observed 
(measured) D values are weighted averages of the free and bound D values [107]. 
In the 2D DOSY spectra (Fig. 23), the F2 dimension shows the chemical shift and F1 
stands for log D. Groups belonging to the same molecule will therefore appear in almost the 
same F1 row. 
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In the molecule of DIMEB, there are =CH2 groups and –O–CH3 groups, which have 
chemical shifts (δ) in the range 1–5 ppm. In the molecule of LOR, there are aromatic protons 
which have higher δ values, at about 7–8 ppm. In the DOSY spectrum of KP 1:1, log D is the 
same for every chemical shift, which is possible only when LOR is complexed in DIMEB, 
when they compose a unit. If LOR is not complexed, it would diffuse more quickly due to its 
small molecular weight; it would have a smaller D value. 
The D value measured for the complex indicates that it is best formulated as the 1:1 
complex. For perfect spheres, theory predicts that increasing the molecular weight n-fold 
should lead to a D value decreased by a factor of n-1/3. Unfortunately, in the absence of well-
defined 1H NMR spectra, X-ray crystallographic results or ESI-MS data, assignment of 
absolute stoichiometry to these aggregates is speculative [108]. 
 
 
Fig. 23 Representative DOSY spectra of KP 1:1 (grey) and KP 1:2 (blue) 
 
6.9 PAMPA 
 
LOR is a highly variable drug from the aspect of BA: its absorption depends greatly 
on the content of the GI tract (fasted or fed state). In the fasted state, different enzymes and 
natural solubilizers (e.g. bile acids) are released, which help to dissolve the drug. All forms of 
ppm l
o
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food have their own acidic (e.g. meats, cheese, egg, alcohol, mustard, sweeties, etc.), basic 
(e.g. potato, carrot, onion, mushroom or coconut) or natural characteristics, which influence 
the pH in the GI tract, and hence the solubility of this ionizable API. The pH of the stomach is 
known to differ significantly among individuals and is within the range of 1 to 3 or even 
higher (1 to 5) under fasting conditions. If undissolved LOR is emptied from the stomach, the 
absorption rate will be dramatically lower as compared with that in individuals where 
complete dissolution occurs in the stomach [90]. 
As LOR is a BCS class II drug, it readily passes through the intestinal wall, with a 
permeability value of 2.7·10-3 – 4.8·10-5 cm/min [90]. The PAMPA model represents only 
passive diffusion, and deceptive results can be observed if other mechanisms also play a role 
in the absorption of the API. LOR is a substrate of P-gp, which hinders its absorption, and 
thus the BA of this molecule. Figure 24 indicates that LOR has higher permeability than the 
DIMEB-containing products. 
The results demonstrate that, if the main force of absorption was passive diffusion, 
DIMEB would hinder this process. It is possible that the diffusion through this artificial 
membrane is bidirectional, and therefore the absorbed LOR can back-diffuse to the donor side 
and become recomplexed by DIMEB. Another explanation is that the stability of the complex 
is too high, and the association-dissociation balance is shifted to association. There is an 
observable relationship between the amount of DIMEB and the calculated permeability. The 
higher the concentration of DIMEB is, the lower the permeability is. This confirms the theory 
that the association-dissociation balance is shifted to association, and the back-diffused LOR 
is recomplexed by free DIMEB. The statistical analysis reveals that the differences between 
the Pe values of LOR and KP 1:1, LOR and KP 1:2, and KP 1:1 and KP 1:2 are significant 
(p<0.05). 
The permeability of LOR rises with increasing pH: at acidic pH, LOR is in a 
protonated form, which cannot pass through the membrane, but at basic pH it is not 
protonated (nonionized), and can be absorbed. This tendency also holds for KP 1:2, but the 
permeability is always lower at each pH value, which corresponds to the above discussion. 
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Fig. 24 Calculated effective permeability values of LOR, KP 1:1 and KP 1:2 
 
 
6.10. In vivo experiments 
 
The main effect of the oedema inducer compound 48/80 is the release of histamine 
from the mastocytes, and hence the effect of the antihistamine LOR can be well examined 
with this model [101, 102]. 
LOR, DIMEB and the inclusion complexes were investigated to establish to what 
extent they can reduce induced oedema. The volumes of the oedema induced in the right back 
paws are presented in Fig. 25. It was found that DIMEB did not influence the extent of 
oedema relative to the control group, and thus the effects of the DIMEB-containing products 
can only be due to the LOR in the products. The compound 48/80-induced oedema has been 
significantly decreased by rats pretreated with LOR, KP 1:1 and KP 1:2. The results of the 
Newman-Keuls multiple comparison test are presented in Table 7. It is evident that the 
abilities of LOR, KP 1:1 and KP 1:2 to decrease oedema differ significantly; the 
complexation of LOR with DIMEB resulted in better BA. 
We also measured the blood concentrations with HPLC. The data shown in Fig. 26 
relate to the effects on oedema, except that the blood concentrations of LOR and KP 1:1 do 
not differ significantly, which demonstrates that KP 1:1 does not reach the desired BA. 
Excess DIMEB (as in KP 1:2) is needed to obtain pH-dependent solubility and more 
consistent and greater BA. 
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LOR was well separated from the biological background under the described 
chromatographic conditions, with mean RT=7.50 min. No interference with plasma matrix 
constituents was observed. The mobile phase used guaranteed good repeatability of the 
retention times. The LOR concentration in samples from the animals is about a few ng/mL, 
and thus the analytical wavelength was selected according to the maximum LOR absorbance 
with respect to a stable baseline. 
P-gp recognizes many compounds as substrates, and tends to have high affinity for 
hydrophobic and positively charged compounds at physiological pH. DIMEB appears not to 
be a substrate of P-gp because it is a hydrophilic and electrically neutral cyclic 
oligosaccharide with a relatively high molecular weight. Furthermore, DIMEB should not 
compete with P-gp substrates due to its lack of cell permeability. Thus, DIMEB must have an 
alternative inhibitory effect on P-gp activity, differing from the P-gp inhibitors that suppress 
the efflux by their surface activity. Some results suggested that DIMEB has a direct inhibitory 
effect on the P-gp level on the cell surface. DIMEB did not exhibit cytotoxicity on Caco-2 
cells and had no effect on the paracellular and transcellular transport [109]. 
Hence, one part of the DIMEB will affect P-gp, and the other part remains for the 
recomplexation. This can be another explanation why there is a need for excess DIMEB to 
achieve much better BA. These two mechanisms probably play a role in the enhanced 
absorption, and therefore in the greater BA. Consequently these observations also suggested 
that the increase in the AUC value of LOR by DIMEB may perhaps be caused not only by the 
solubilizing activity of DIMEB, but also by inhibition of the efflux in the GI tract. 
 
Table 7 Results of the Newman–Keuls Multiple Comparison Test 
Comparisons Mean difference Q P value 
Control vs. DIMEB –2.333 1.097 >0.05 
Control vs. LOR –60.83 30.08 <0.001 
Control vs. KP 1:1 –70.33 33.08 <0.001 
Control vs. KP 1:2 –81.43 35.98 <0.001 
LOR vs. KP 1:1 –9.50 4.015 <0.01 
LOR vs. KP 1:2 –20.60 8.273 <0.001 
KP 1:1 vs. KP 1:2  –11.10 4.311 <0.01 
P>0.05 = non–significant (ns.), P<0.05 = *, P<0.01 = **, P<0.001 = *** 
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Fig. 25 Oedema decreasing effect of LOR and selected KPs in rats 
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7. Summary 
 
The aim was to increase the solubility, dissolution rate and BA of the investigated API (LOR) 
by means of several pharmaceutical technological methods. This work involved a 
preformulation study to introduce the technological possibilities of a generic formulation. 
 
The research work can be summarized as follows: 
 
1. From the available 9 CD derivatives DIMEB was chose based on preliminary 
experiments, since it increased the solubility of LOR to the largest extent, to about 300–
fold. 
2. Different molar ratios (LOR:DIMEB = 1:1, 1:2 and 1:3) and four methods (PMs – 
physical mixtures, KPs – kneaded products, MWs – microwave products and SDs – 
spray dried products) were applied to form complexes. Besides solid dispersions with 
PVP K25 were also made in four different mass ratios (LOR:PVP K25 = 1:1, 1:2, 1:4, 
1:6). 
3. The utmost dissolution was obtained by the higher amount of DIMEB containing 
products (1:2 and 1:3 compositions). From the preparation methods, no more than the 
physical mixing and the solid dispersions with PVP K25 did not show much better 
results than LOR on its own. 
4. With the application of DIMEB pH-independent solubility of LOR was achieved by 
some of the compositions (KP, MW, SD: 1:2 and 1:3), therefore better and smoother 
bioavailability can be expected. 
5. The extent of inclusion complexation has been proved by indirect (DSC, FT-IR, DOSY) 
and direct (ESI-MS) methods. For PMs there is only particular complexation, while in 
case of KPs, MWs and SDs full complexation occurred. The stoichiometry of these 
complexes is 1:1 based on the ESI-MS and DOSY results, which can be seen on the 
phase solubility diagram, as well. 
6. The physical and chemical characteristic of KP and MW are quite similar, the 
thermoanalytical and FT-IR studies proved that the microwave power did not cause any 
physical or chemical change in the molecule of LOR. 
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7. By the in vitro membrane modelling (PAMPA) it has been proven that the absorption of 
LOR is not only affected by passive diffusion, nevertheless other mechanisms also play 
role in this process. 
8. With in vivo experiments the KP 1:1 and 1:2 decreased the extent of the induced 
oedema, i.e. improved the BA of LOR, as a result of some factors: products has better 
dissolution, the dissolution of the products has become independent of the 
gastrointestinal pH and DIMEB inhibits the P-gp (which effluxes the absorbed LOR, 
therefore the BA is low and very variable). It has been proven that there is a need for 
excess amount of DIMEB (1:2 composition) to achieve the best pharmacological effect 
although the stoichiometry of the complex is 1:1. 
9. The obtained results are very useful in the early drug discovery. Most of the new APIs 
are very hydrophobic and some of them have an ionizable function group, i.e. pH-
dependent solubility and in these cases DIMEB can be a good choice to improve their 
solubility, so they could become suitable for other important investigations, like 
toxicological studies, effectiveness assays and so forth. 
 
 0 
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a b s t r a c t
The majority of active pharmaceutical ingredients are poorly soluble in water. The rate-determining step
of absorption is the dissolution of these drugs. Inclusion complexation with cyclodextrin derivatives can
lead to improved aqueous solubility and bioavailability of pharmacons due to the formation of co-crystals
through hydrogen-bonding between the components. Inclusion complexes of loratadine were prepared
by a convenient newmethod involvingmicrowave irradiation and the productswere comparedwith those
of a conventional preparation method. Dissolution studies demonstrated that the solubility and rate of
dissolution of loratadine increased in both of themethods used. The interactions between the components
were investigated by thermal analysis and Fourier Transform Infrared studies. The microwave treatment
did not cause any chemical changes in the loratadine molecule.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
It is estimated that 40% or more of active pharmaceutical ingre-
dients identiﬁed through combinatorial screening programs are
poorly soluble in water [1]. The bioavailability of drugs depends
on their solubility and permeability. The drugs belonging in class
II of the Biopharmaceutical Classiﬁcation System have high mem-
brane permeability, and the limiting factor of their absorption is
therefore their solubility [2].
One of the methods applied to increase solubility is to pre-
pare inclusion complexes with cyclodextrins (CDs) [3–5]. Such
complexes have found extensive application in many ﬁelds, includ-
ing pharmaceutical technology (to increase the aqueous solubility,
dissolution rate, bioavailability and stability of drugs, to reduce
bitterness and to decrease tissue irritation upon dosing) [6]. CDs
are usually used for solubility enhancement from the preclinical
stage during drug development. The methods widely utilized to
prepare inclusion complexes are coprecipitation, kneading, freeze-
drying and co-grinding [7]. They often involve time-consuming
manufacturing processes and generally require large amounts of
solvents. There is therefore a need for faster and more conve-
nient processes for the preparation. Microwave (MW) irradiation,
∗ Corresponding author. Tel.: +36 62 545 577;fax: +36 62 545 571.
E-mail address: aigner@pharm.u-szeged.hu (Z. Aigner).
a method recently used to prepare CD inclusion complexes, has
the major advantages of shorter reaction times and higher yields
of products [8]. In pharmaceutical technology, MW has been
used because of its thermal effect in drying processes (granules
or crystals), and for the sterilization of injections and infusions
[9–11].
Loratadine (LOR) (Fig. 1) is a second-generation tricyclic H1
antihistamine, marketed for its non-sedating properties. H1 anti-
histamines prevent and suppress the responses to histamine or
allergen in the nose and conjunctivae, thereby eliminating such
symptoms as itching, congestion, rhinorrhoea, tearing and sneez-
ing [12]. The solubility of LOR depends on the pH: on increase of
the pH, the solubility decreases exponentially. Because of this, its
bioavailability exhibits high variability, which is a disadvantage for
its oral administration [13] because the drug may suffer a reduced
therapeutic efﬁcacy.
In general kneading,which is a simple and scaleable preparation
method, gives the best results [14], but in this case the removal
of the solvent could be a critical parameter in the preparation.
In the present work the applicability of MW irradiation to pre-
pare inclusion complexes without chemical change was studied.
The conventional (kneaded product; KP) and a convenient prepa-
ration technique using MW irradiation treatment were compared
in the case of LOR+dimethyl--CD (DIMEB) inclusion complexes.
Dissolution studies were performed with the paddle method,
and the interactions of the components were investigated by
0731-7085/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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Fig. 1. Chemical structure of loratadine.
thermoanalytical methods [15] and Fourier Transform Infrared (FT-
IR) spectrometry.
2. Materials and methods
2.1. Materials
Heptakis-2,6-di-O-methyl--cyclodextrin (DIMEB) was pur-
chased from Cyclolab (Fig. 2); LOR (ethyl 4-(8-chloro-5,6-dihy-
dro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidine)-1-piperi-
dinecarboxylate) was kindly provided by TEVA Pharmaceutical
Industries Ltd. (Hungary); other chemicals were of analytical
reagent grade purity.
2.2. Preparation of products
Homogeneous powder mixtures of LOR and the appropri-
ate amount of DIMEB were prepared in three molar ratios
(LOR:DIMEB=1:1, 1:2 and 1:3), the same mass of 50% alcohol
was then added to the mixtures, and they were next homog-
enized, and treated in a MW oven (Milestone Ethos TC MW
apparatus, Advanced Microwave Labstation, Italy). The method
of MW treatment was as follows: 150W, 90 s, 60 ◦C, and the
samples were then dried under vacuum [7]. As a control KPs
were made: the physical mixtures were suspended in the same
mass of 50% ethanol, and the solvent was evaporated of at room
temperature. The products were ground and sieved (100m),
and stored at room temperature under normal conditions. The
Fig. 2. Chemical structure of DIMEB.
actual LOR load of products was determined spectrophotometri-
cally.
2.3. Dissolution study
In vitro dissolution studies (min. three parallel measurings)
were performed in simulated intestinal medium (SIM) (phosphate
buffer; pH 7.0±0.1; 0.1M) using the modiﬁed rotating paddle
method. 50mg of LOR, or product containing 50mg of LOR (consid-
ering the LOR load of products and water content) was measured
and added to 100ml of SIM (100 rpm at 37±0.1 ◦C). Aliquots were
withdrawn at 5, 10, 15, 30, 60, 90 and 120min and immediately
ﬁltered. At each sampling time, an equal volume of fresh SIM
was added, and the correction for the cumulative dilution was
calculated. The concentration of LOR was measured spectropho-
tometrically at 248nm after the suitable dilution (Unicam UV/VIS
spectrometer, Unicam, UK). The calibration curve was determined
between 0 and 28g/ml, the slope was 0.0366, the linearity (r2)
was 0.9997. There was no absorption of DIMEB at the absorption
maximum of the LOR. The limit of quantiﬁcation (LOQ) value was
500g/l.
2.4. Thermoanalytical studies
2.4.1. Differential scanning calorimetry (DSC)
The DSC records were obtained with a Mettler Toledo DSC 821e
apparatus. Between2and5mgof samplewas crimped ina standard
aluminumpan (40l) andheated from25 to300 ◦Cat aheating rate
of 5 ◦C/min under a constant purge of argon at 10 l/h.
2.4.2. Thermogravimetric measurements
The TG, DTG and DTA curves were recorded in parallel in plat-
inum crucibles with the same thermal program (heating range
25–300 ◦C, heating rate 5 ◦C/min), using a MOM Derivatograph-
C (MOM Co., Hungary). The reference was a crucible containing
aluminum oxide.
2.5. FT-IR analysis
The sample with a LOR content of 0.5mg was ground and mixed
with150mgofdryKBr in anagatemortar, and themixturewas then
compressed into a disc at 10 t. Each disc was scanned 64 times at a
resolution of 4 cm−1 over the wavenumber region 4000–400 cm−1
with an FT-IR spectrometer (ThermoNicolet AVATAR330,USA). The
evaluation was carried out with the GRAMS/AI Ver. 7 program.
3. Results and discussion
3.1. Dissolution study
The investigated active pharmaceutical ingredient LOR has
different solubility properties at the various pH levels in the gas-
trointestinal tract. LOR can undergo protonation on the N of the
pyridine ring in acidic media, forming salts with good solubility; in
contrast, in SIM it is practically insoluble (0.38mg/100ml). Since
LOR is a weak base, it is absorbed from the intestine. Accordingly,
the dissolution properties were studied in SIM. The dissolution
curves are demonstrated in Fig. 3. For both the KP and MW prod-
ucts, the dissolution rate and the solubility of LOR depended on the
molar ratio. At 1:1, the quantity dissolved was about 60%, whereas
for the 1:2 and 1:3 products close to 100% release was observed.
These investigations revealed that the KP and MW products yield
similar dissolution results.
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Fig. 3. Dissolution of loratadine in simulated intestinal medium.
3.2. Thermal analysis
The sharp, narrow endothermic peak in the DSC spectra of
LOR (peak 133.16 ◦C, normalized melting enthalpy 89.48 J g−1) and
LOR MW (peak 135.48 ◦C, normalized melting enthalpy 65.94 J g−1)
denotes the melting point of the material. There was no signiﬁcant
difference between the treated and the untreated LOR. Accord-
ing to the TG curves, practically none of them contains residual
water. The stability of the LOR was not affected (no degrada-
tion was observed) up to 300 ◦C. DIMEB is amorphous, and there
is no thermoanalytical indication of the temperature of melting
point of the LOR, but it has an exothermic peak which reﬂects
the recrystallization of DIMEB at 181 ◦C (loss in mass was not
detected in the TG curve). The water content of DIMEB is about
0.9%. The results of DSC investigations are presented in Fig. 4. No
endotherm was detected for the LOR:DIMEB products at around
the temperature of the melting point. Thus there are two possible
explanations for the MW products: the samples were amorphized
during the preparation method, or total complexation occurred.
For the KPs, similar phenomena could be observed, but there is
no possibility for amorphization during the slow drying. For the
products the exotherm due to DIMEB was observed to have moved
to lower temperature (about 170 ◦C). This phenomenon was seen
for both KPs and MWs, and it can therefore be stated that the
MW did not cause changes in the chemical structure of the LOR
molecule. The water content of the KPs and MWs was similar, their
quantity was about 0.9–2.7% and increased with the rising of CD
ratio.
3.3. FT-IR spectra
The spectral changes were evaluated by subtraction of the
spectrum of DIMEB from the spectra of the samples. The spec-
tra of treated and untreated LOR and the calculated subtraction
spectra are presented in Fig. 5. The spectra of the products
involving different molar ratios and preparation methods did
not differ appreciably. For all of the products, the character-
istic C O stretching frequencies (1702 cm−1) were shifted to
lower wavenumbers, and the typical C–O stretching at 1226 cm−1
was shifted to the higher range. These results lead us to
Fig. 4. DSC curves of loratadine and products.
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Fig. 5. FT-IR spectra of loratadine products.
surmise, that the –COO group provides the complex-forming
bonds and that complex formation alters the hydrogen-bonded
cyclic dimer structure of the carboxyl group. In accordance
with the DSC ﬁnding, DIMEB forms an inclusion complex with
LOR.
4. Conclusions
The inclusion complexes of LOR prepared with the appli-
cation of MW irradiation were compared with those prepared
by a conventional method. During the formation of the inclu-
sion complex, hydrogen bonds develop between LOR and DIMEB,
and the inclusion complex can therefore be regarded as co-
crystals [16]. On inclusion complex formation, the solubility
and rate of dissolution of LOR were increased. The interac-
tions between the components were demonstrated by thermal
analysis and FT-IR studies. The results were similar for the
materials made by the two different preparation methods, but
MW irradiation has several advantages. The drying time is sub-
stantially shorter, and on an industrial scale up it is therefore
simpler to handle the greater quantities, and the MW irra-
diation method can accelerate the preparation of preclinical
samples from poorly water-soluble drugs and CDs. MW irradiation
treatment has proved to be a suitable technique for the prepa-
ration of CD inclusion complexes, yielding products with good
bioavailability.
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Polyvinylpyrolidone as Carrier to Prepare Solid
Disperssion - pros and Cons
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Enhancement of the solubility of poorly-soluble drug substances is one of the most important tasks in
pharmaceutical technology. It is possible to solve this problem with new drug carrier systems and/or with
new technological processes. The solid dispersion technology is generally accepted technique which is able
to enhance the dissolution characteristics of drugs with poor water solubility. For this purpose, the drug
substance is dispersed in a water-soluble inert polymer matrix; at the higher surface area, due to the
presence of the polymer, sometimes the drug solubility and dissolution rate may increase. This work
summarizes the theoretical basics of solid dispersion technology and introduces pros and cons of studies
using polyvinylpyrrolidone (PVP) as a carrier in the cases of two chosen active pharmaceutical ingredients
(APIs), nifluminic acid (NIF) and loratadine (LOR). Wettability properties and dissolution were characterized.
The drug-polymer interaction was investigated by using differential scanning calorimetry, and powder X-ray
diffraction. Even though the instrumental examinations show similar results for both drugs, the dissolution
rate improved only by NIF significantly. The explanation for this phenomena could be sought in the different
chemical structure and the strength of the connection between the PVP and the drugs
Keywords: polyvinylpyrrolidone, nifluminic acid, loratadine, solid dispersion, DSC, X-ray, dissolution
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Drug absorption from a solid dosage form after oral
administration depends on the release of the drug product,
the dissolution or solubilization of the drug under
physiological conditions, and the permeability across the
gastrointestinal tract. On the basis of their solubility and
permeability, drugs can be divided into high/low solubility-
permeability classes (biopharmaceutical classification
system, BCS). If a drug candidate has reasonable
membrane permeability then often the rate-limiting
process of absorption is the drug dissolution step   [1, 2]. To
focus on formulation of classes II API, can also be used to
develop a more optimised dosage form based on
fundamental mechanistic features. Therefore there is a
special importance of solid dispersion technology, too.
NIF (fig. 1.), an anthranilic acid derivative, is a frequently
used anti-inflammatory drug, which also has a weak
analgesic effect. It is primarily used to treat different forms
of rheumatism, e.g. rheumatoid arthritis and arthrosis, and
to decrease other inflammatory phenomena. It has some
side-effects, such as nausea or vomiting [3]. According to
the BCS, NIF can be considered a class II compound, i.e. a
water-insoluble, lipophilic and highly permeable drug [4].
Since NIF is also widely prescribed for mild illnesses, the
safety aspect becomes more and more important and
efforts should be made to optimise the overall drug
pharmacological profile.
LOR (fig. 1.) is a second  generation of antihistaminic
active substance. Loratadine is a long-acting antihistamine
that blocks the actions of histamine that causes some of
the symptoms of allergic reactions. It is one of a few
antihistamines that doesn’t cause sedation. Headache,
fatigue, dry mouth, thirst, dry nose or hoarseness may occur
as side effects. It belongs to the second group of the BCS,
too. The solubility depends on the pH of the gastrointestinal
liquid [5], so the bioavailability is very variable.
The concept of preparation of solid dispersions to
improve the dissolution rate of sparingly soluble drugs has
been widely explored since 1961 [6]. The drug-carrier
interactions were classified into six representative
structures: simple eutectic mixtures; solid solutions; glass
solutions and glass suspensions; amorphous precipitations
in a crystalline carrier; compound or complex formation;
or combinations of these [7].
The frequently used procedures to prepare solid
dispersions are the melting and solvent techniques. By the
hot melt method the thermostability of the drug limits the
application of this method. With the discovery of the
solvent method, many of the problems associated with
the melting method were solved. Those polymers that
could not be utilized for the melting method because  their
high melting range (e.g. PVP) could now be considered as
carrier possibilities [6, 8]. Finding  the suitable drug carrier,
the wettability of the product will be increased, and the
better microenvironment conducives to dissolving of API
[9, 10, 11, 12].
PVP (fig. 2.) is an amorphous carrier and it is suitable for
formulate solid solutions, glass solutions and amorphous
precipitations with a crystalline API. The glass transition
Fig. 1
Chemical structure of NIF and LOR
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temperature (Tg) is high and for this reason PVPs have only
limited applications for the preparation of solid dispersions
by the hot-melt method. Due to their good solubility in a
wide variety of organic solvents, they are particularly
suitable for the preparation of solid dispersions by the
solvent method [13]. The aim of the preparation of PVP
solid dispersions is generally to transform the drug into the
amorphous form and thus to achieve faster dissolution.
Dispersions containing crystalline areas exhibit biphasic
release profiles, with the amorphous areas dissolving
quickly and the crystalline areas more slowly. For example,
for a crystalline drug with a very poor aqueous solubility,
the formation of an amorphous mixture with a water-
soluble additive can provide an opportunity to enhance the
dissolution and perhaps bioavailability [14].
In the cases of both drugs cyclodextrin complexation
was used to improve the solubility and dissolution rate [15,
16], which was good enough by LOR, but more less in
case of NIF. Other possibility is the solid dispersion
technology. However this paper will show the interactions
between PVP and the APIs, which have different chemical
properties and variant behaviour in the gastrointestinal
liquids.
Experimental part
Materials
Nifluminic acid: 2-[[3-(trifluoromethyl)phenyl]amino]-
3-pyridine-carboxylic acid (G. Richter Pharmaceutical
Factory, Hungary); Loratadine: ethyl-4-(8-chloro-5,6-
dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-
ylidene)-1-piperidinecarboxylate (TEVA Hungary Ltd.);
polyvinylpyrrolidone (PVP): Plasdone K-25 (Mw ~ 34000,
Tg ~ 160 
oC), (C/o ISP Customer Service GmbH, Germany).
Other chemicals: methanol and acetone (Reanal Co.,
Budapest, Hungary).
Methods
Preparation of the samples
The solid dispersions of NIF in PVP K-25 containing four
different ratios (1:1, 1:2, 1:4 and 1:6 w/w) were prepared
by the solvent method (NIF SD). To a solution of NIF (1.0 g)
in 30 mL of acetone, the appropriate amount of PVP K-25
was added. The minimum amount of methanol was added
to solubilize the polymer. The solvents were then removed
by evaporation under reduced pressure at 30oC and the
residue was dried under vacuum at room temperature for
3 h [17]. The abbreviation SD refers the solid dispersion
product by the solvent evaporation method.
The solid dispersions of LOR were prepared with the
same ratios (LOR SD). LOR and PVP K-25 were solved in
methanol and the solvent was removed by vacuum dryer
during 6 h.
The physical mixtures (PMs) by both of the drugs as a
control were mixed according to the ratios. All of the
products were pulverized in a mortar and sieved through a
100μm sieve.
Method of DSC
The DSC measurements were performed by a Mettler
Toledo DSC 821e thermal analysis system with the STARe
thermal analysis program V6.0 (Mettler Inc.,
Schwerzenbach, Switzerland). Approximately 2–5 mg of
pure drug or product was examined in the temperature
range between 25 oC and 300 oC. The heating rate was 5 oC
min-1. Argon was used  as  carrier gas,  at a flow rate of 10
L/h.
Hot-stage microscopy (HSM)
Microscopic observations of morphological features and
their changes during heating were carried out with a LEICA
Thermomicroscope (LEICA MZ 6, Germany). The samples
were observed under the microscope by using a scanning
speed of 2°C/min. The magnification in the photographs
was 59.7x.
X-ray powder diffraction (XRPD)
The physical state of the NIF and LOR in the different
samples was evaluated by XRPD. Diffraction patterns were
obtained on a Philips PW 1710 diffractometer, where the
tube anode was Cu with Kα = 1.54242 Å. The pattern was
collected with a tube voltage of 50 kV and 40 mA of tube
current in step scan mode (step size 0.035, counting time
1 s per step).
Study of contact angles
The OCA Contact Angle System (Dataphysics OCA 20,
Dataphysics Inc., GmbH, Germany) was uSDd for studies
of the wettability of NIF, LOR and their products. 0.15 g of
material was compressed under a pressure of 1 ton by a
Specac hydraulic press (Specac Inc., USA). The wetting
angles of the pressings were determined after 4.3 μL of
distilled water was dropped onto the surface of the
pressings. The change in the wetting angle was registered
from 1 to 25 s (minimum of 5 parallel times), using the
circle fitting method of the OCA System.
Methods of in vitro dissolution
The modified paddle method with the USP dissolution
apparatus (Erweka Type DT, Germany) was used to
examine 200 mg samples of pure NIF, LOR or products
containing 200 mg of drugs in 100 mL of simulated gastric
medium (SGM) (pH = 1.1 ± 0.1; 94.00 g of 1 M HCl, 0.35 g
of NaCl, and 0.50 g of glycine to 1000 mL with distilled
water), simulated intestinal medium (SIM) (pH= 7.0 ±
0.1; 14.4 g of Na2HPO4·2H2O, and 7.1 g of KH2PO4 to 1000
mL with distilled water). The paddle was rotated at 100
rpm and sampling was performed up to 120 min (sample
volume 5.0 mL). After filtration and dilution, the drug content
of the samples were determined spectrophotometrically
(SGMNIF = 256 nm, SIMNIF = 288 nm and SGMLOR = 276 nm,
SIMLOR = 248 nm). Previously the wavelengths of
maximum absorption depending on pH were determined
by calibration in the concentration-range between 0 and
28 μg/mL with 3 parallel measurements.
Results and discussion
Results of thermalanalysis
Figure 3. shows the DSC curves of NIF, LOR, PVP K-25
and their products. NIF gave a melting endotherm at 201.95
oC, which can be identified from the literature data as its
melting point. The onset of melting was observed at 201.15
oC and the end at 203.81oC; the normalized enthalpy was
127.11 J g-1. After the melting of NIF, the total mass of the
investigated sample was progressively lost, with an
Fig. 2. Structure of PVP
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endotherm at about 250oC relating to its decomposition.
LOR has lower melting point at 133.16oC with 132.13oC
onset and 134.44 oC endset and the normalized enthalpy
was 90.05 J g-1. The DSC curves did not reveal a melting
peak for NIF in any of the solid dispersions and reference
PMs. This may be due to the interaction between NIF and
PVP in these systems. In contrast with the XRPD patterns
of the NIF PMs (without any amorphous character of NIF),
the melting point of the drug was not observed on the DSC
curve. This indicated a NIF:PVP solid-state interaction
induced by heating. However all curve of LOR PMs
presented   a little  shifted   endotherm  peak  at   around
133oC. In the cases of LOR SDs this phenomena wasn’t
detected, so they referred amorphous character of the drug,
except the 1:1 product.
To visualize the changes in the NIF and LOR PM samples
during heating, HSM was used. This technique is
complementar y to DSC and may facilitate the
interpretation of the DSC results. With increase of
temperature, the PVP began to melt, and above 150 oC its
melting was complete. It may be seen that the NIF particles
were dispersed in the melt and subsequently dissolved with
rising temperature. During heating, the drug particle size
was steadily reduced, showing its dissolution in the PVP
melt. The NIF was completely dissolved in the melt of PVP
at close to 157oC, a temperature about 50 oC lower than
the melting point of the pure drug. This finding can explain
the absence of any sign of melting in the DSC thermograms
of the PM. But this phenomena wasn’t detected by LOR
PMs, because LOR has melted before the Tg of PVP
(~160oC), so it has not the possibility to dissolve in the
melted PVP.
XRPD study
The XRPD patterns of APIs, PVP K-25, PMs and SDs in
1:6 ratio are shown in figure 4. PVP is an amorphous
Fig. 3
DSC curves of APIs and products
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Fig. 5. Dissolution of NIF and its products in SGM and of LOR and its products in SIM
powder without crystalline structure. The presence of
numerous distinct peaks in the XRPD spectrum indicates
that NIF and LOR are crystalline materials. NIF has
characteristic peaks at diffraction angles 2θ at 8.18, 12.92,
16.33, 21.30 and 23.21o. In the case of LOR we can see
sharp peaks at 15.15, 19.45, 21.11, 23.84, 24.38 and 30.44o.
The XRPD peaks of NIF in the PMs K-25 were similar to
those for the pure drug, indicating that the crystallinity of
NIF was not changed in these products. However, the
crystalline structures of NIF in all the solid dispersions were
different from that of the pure drug, as revealed by the
differences in their XRPD patterns. These patterns were
similar to those for the PVPs. The absence of diffraction
peaks indicated the presence of NIF in amorphous form.
By the LOR PMs the characteristics reflections can be
identified well. As the DSC curve of LOR SDs shown the
possibility of amorphous character, we saw this
phenomenon on XRPD pattern too, except of LOR SD 1:1,
where the PVP concentration was the smallest, so it was
not enough to inhibit the crystallization of LOR. Figure  4
presents that PVP K-25 and LOR SD 1:6 are amorphous.
The intensity of amorphous ring (by 22 degree) are the
Fig. 4. XRPD patterns of APIs and 1:6 products
same by these samples, but the reflection (by 11 degree)
of LOR SD 1:6 is half of the pure PVP.
Studies of wettability and dissolution tests
The contact angles at 5 s for NIF, LOR and their SDs
were evaluated. The contact angle for NIF was 71.1o and
for LOR was 73.1 o, i.e. they are very hydrophobic drugs.
The contact angles of the investigated products were in all
cases decreased. The investigation of the systems
produced by NIF SDs revealed that, with increasing PVP
content, the contact wetting angles increased. However
in the cases of LOR SDs with increasing PVP content, the
contact wetting angles were similar to each other. The
NIF SD 1:1 (7.5o) and LOR SD 1:6 (38.04 o) gave the best
results. Based on these results we can conclude that a
better  expected  wettability may will resulted in better
dissolution (table I.).
Solubility characteristics of NIF and LOR are different in
the gastrointestinal media, so we investigated their
dissolution in that media in which the API has worse
solubility. Unfortunately both APIs are absorbed from that
part of gastrointestinal tract, in which they don’t dissolve
Table 1
THE CONTACT ANGLES OF NIF, LOR AND THEIR PRODUCTS
REV. CHIM. (Bucureºti) ♦ 60♦ Nr. 6 ♦ 2009
well. The dissolution from these media could improve by
technological methods. Figure 5 presents the dissolution
results of drugs and products from their adequate
“absorption media”. Nearly 3,5 times better dissolution was
detected in the case of NIF SDs in SGM and in addition the
dissolution of NIF SD in SIM was complete and it means
that after the increased dissolution from gastric medium
we could reach quantitative absorption from the intestine.
But LOR SDs did not give much better result. The dissolution
didn’t change in SIM, where 1:1 and 1:2 ratios worsened
the dissolution compared with raw drug. In the case of 1:4
and 1:6 product the initial appearance of increased
dissolution rate can be explained by the fact  the fact that
amorphous drug dissolves faster than the crystalline LOR,
and after the rapid dissolution the API recrystallizes.
This might be due to the surface tension-lowering effect
of PVP, resulting in wetting of the hydrophobic crystalline
surface [18]. This should retard any agglomeration or
aggregation of the particles, which can slow the dissolution
process. Differences were observed according to the
investigated APIs. In the case of LOR significant dissolution
increasing was detected in neither media.
Conclusion
In consequence of the poor water-solubility of the
pharmaceutical ingredients, NIF and LOR, our aim was to
increase their solubility and dissolution rate to form solid
dispersions. PVP   K-25 was used to reach amorphous
drugs. It could be interpreted that the solvent evaporation
method not always resulted in products with excellent
dissolution. However the amorphisation was successful in
the cases of both  drugs, the increasing of dissolution was
reached only by NIF. The PVP presents an apolar medium
for LOR, and as LOR is a lipophil drug, it rather likes to stay
in an apolar medium, than to go to the hydrophilic, aqueous
medium. And in the case of LOR we need to optimise the
amount of PVP too, because too much PVP inhibits the
dissolution of API and too less isn’t enough to increase the
dissolution.
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Abstract A tricyclic, piperidine derivative of antihista-
mines, loratadine, which belongs in class II of the
Biopharmaceutical Classification System, was investigated.
It is an ionizable drug, whose solubility depends on the
gastrointestinal pH, and the bioavailability is therefore very
variable. The aim of this work was to enhance the disso-
lution and make the solubility of loratadine independent of
pH. Inclusion complexes were prepared between loratadine
and dimethyl-b-cyclodextrin in two different molar ratios
by three techniques (physical mixing, kneading and spray-
drying). The formation and physicochemical properties of
the inclusion complexes were investigated by means of
dissolution tests, thermal analysis and Fourier Transform
Infrared spectroscopy. The instrumental examinations
proved the presence of partial or total complexes depend-
ing on the preparation method and molar ratio, which
resulted in better dissolution. For some compositions and
preparation methods, the application of this cyclodextrin
made the solubility of loratadine independent of pH.
Keywords Loratadine  DIMEB  pH-independent
solubility  Thermal analysis  FT-IR  Co-crystal
Introduction
It is estimated that 40% or more of active pharmaceuti-
cal ingredients (APIs) identified through combinatorial
screening programs are poorly soluble in water [1]. The
bioavailability of pharmacons is determined by their solu-
bility and permeability. All drugs must possess some
degree of aqueous solubility in order to be pharmacologi-
cally active, and they need to be lipophilic to be able to
permeate biological membranes [2]. The rate-limiting step
of oral absorption is the dissolution by APIs with solubility
\0.1 mg/mL, e.g. drugs belonging in classes II and IV of
the Biopharmaceutical Classification System (BCS) [3, 4].
The solubility of ionizable compounds varies with the pH
of the gastrointestinal juices, depending on their pKa [5].
The pH of the gastrointestinal fluids is therefore one of the
most important factors influencing on the saturation solu-
bility of ionizable drugs [6]. As the pharmacon proceeds
along the gastrointestinal tract, it passes into a medium
with somewhat higher pH. During 90% of a fasting state,
the gastric pH is \3 [7]. The presence of food in the
stomach can influence the release, dissolution and gastro-
duodenal transport of a drug [8]. As the gastrointestinal pH
can vary widely, the rate of dissolution of an ionizable
pharmacon will also vary considerably. Only the dissolved
drug is capable of absorption, so its bioavailability,
and hence the pharmacokinetic parameters will be very
variable [9].
The investigated API was loratadine (LOR), a second-
generation antihistamine marketed for its non-sedating
properties. H1 antihistamines are applied in the treatment of
allergies: they prevent symptoms such as itching, conges-
tion, rhinorrhoea, tearing and sneezing [10]. LOR belongs
in class II of the BCS [11]. LOR is a weak base; its pKa
value at 25 C has been reported as 4.85–6.00 [10–14]. The
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solubility of bases increases with decreasing pH at pH
values less than the pKa [5]. At lower pH values, LOR,
which is a nitrogen base, is protonated, and therefore
becomes more soluble in water [12]. According to the
modified Hendersson-Hasselbach equation [15], bases are
totally ionized at lower pH values, and at *pH 7 and
higher they are totally unionized, which is the form able to
absorb, so LOR will probably absorb from the intestines, in
which it has poor solubility.
There are several possibilities via which to increase the
solubility of such APIs: the particle size reduction of fe-
nofibrate resulted in a nanodispersion, and enhanced its
bioavailability; and formation of an appropriate indinavir
salt improved the stability and the aqueous solubility of the
compound [16]. Complexation with cyclodextrins (CDs) is
another method applied to improve the aqueous solubility of
drugs [17–20]. The chemical structures of the CDs, their
high molecular weights and their very low octanol/water
partition coefficients are all characteristics of compounds
that do not readily permeate biological membranes [21, 22].
However, the methylated b-CDs are able to permeate and
enhance drug delivery through biological membranes [23].
The effects of CDs on oral drug absorption can be explained
in the context of the BCS [24]. The permeation of BCS class
II drugs through the aqueous diffusion layer is slow due to
their low aqueous solubility. Water-soluble CD complexes
of these drugs exhibit enhanced diffusion to the mucosal
surface, leading to enhanced oral bioavailability [2].
The primary aim of the present work was to improve
the solubility and dissolution rate of LOR, and to make the
solubility independent of pH, thereby enhancing the bio-
availability. We therefore prepared various CD inclusion
complexes of LOR in different molar ratios by three prepa-
ration methods. The investigations of the inclusion complexes
included thermal analysis, Fourier-Transform Infrared
(FT-IR) spectrometry, solubility and dissolution tests.
Materials and methods
Materials
a-CD, b-CD, c-CD, randomly methylated-b-CD (RAMEB),
2-hydroxypropyl-b-CD (HPBCD), methyl-b-CD, hydroxy-
butyl-b-CD and heptakis-(2,6-di-O-methyl)-b-cyclodextrin
(DIMEB) were purchased from Cyclolab Ltd. (Budapest,
Hungary), sulfobutyl-ether-b-CD (Captisol) originated
from CyDex Pharmaceuticals Inc. (Lenexa, USA). LOR
(ethyl 4-(8-chloro-5,6-dihydro-11H-benzo-[5, 6]-cyclohep-
ta[1,2-b]pyridin-11-ylidine)-1-piperidine-carboxylate) was
kindly provided by TEVA Pharmaceutical Industries Ltd.
(Hungary). Other chemicals were of analytical reagent grade
purity.
Methods
Preliminary experiments
The effects of the various CD derivatives on the solubility
of LOR were investigated. 20 mg LOR and 200 mg of the
CD derivatives were suspended in 20 mL of distilled water.
The mixture was stirred at 10 min with a magnetic stirrer
and then filtered, and after suitable dilution the UV spec-
trum was recorded in the range 220–300 nm.
Phase-solubility studies
The phase-solubility diagrams were recorded by the Hig-
uchi-Connors method [3]. For this purpose aqueous
solutions of CDs of various concentrations were prepared
at a specific pH value (7.5) (250 mL of 0.2 M KH2PO4,
204 mL of 0.1 M NaOH made up to 1,000 mL with dis-
tilled water). An excess amount of LOR was added to these
solutions, and they were then shaken at room temperature.
After 72 h, the suspensions were filtered through 0.45 lm
membrane filters. After dilution, their absorption was
measured by UV spectrophotometry (k = 248 nm). The
presence of the CD did not disturb the spectrophotometric
assay. Each experiment was performed in triplicate.
Preparation of the products
DIMEB proved to demonstrate the best enhancement of the
solubility (see Sect. ‘‘Preliminary experiments’’). The
products were prepared in two molar ratios (LOR:DIM-
EB = 1:1 and 1:2) by three methods: physical mixing,
kneading and spray-drying. Physical mixtures (PMs): LOR
was mixed carefully in a mortar with the calculated amount
of CD. Kneaded products (KPs): the physical mixtures
were suspended with the same mass of 50% ethanol, and
the solvent was evaporated off at room temperature. After
drying, the products were ground. Spray-dried products
(SDs): the physical mixtures were dissolved in 50% etha-
nol, and SDs were obtained by using a Bu¨chi Mini Dryer
B-191 (BU¨CHI Labortechnik AG, Flawil, Switzerland), at
an inlet temperature of 105 C, with a compressed air flow
of 800 L/h and a nozzle diameter of 0.5 mm. The aspirator
rate was 75–80%, and the pump rate was 5–10%. All of the
samples were sieved (100 lm) and stored at room tem-
perature under normal conditions.
In vitro dissolution studies
The modified paddle method with the USP dissolution
apparatus (Erweka Type DT, Germany) was used to
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examine 200 mg samples of pure LOR or products con-
taining 200 mg of LOR in 100 mL of simulated gastric
medium (SGM) (pH = 1.1 ± 0.1; 94.00 g of 1 M HCl,
0.35 g of NaCl, and 0.50 g of glycine made up to
1,000 mL with distilled water) or simulated intestinal
medium (SIM) (pH = 7.0 ± 0.1; 14.4 g of Na2HPO4 
2H2O and 7.1 g of KH2PO4 made up to 1,000 mL with
distilled water). The paddle was rotated at 100 rpm and
sampling was performed up to 120 min (sample volume
5.0 mL). After filtration and dilution, the LOR contents
of the samples were determined spectrophotometrically
(kSGM = 276 nm, kSIM = 248 nm).
DSC
The DSC records were obtained with a Mettler Toledo
DSC 821e (Mettler Inc., Schwerzenbach, Switzerland)
apparatus. Between 2 and 5 mg of sample was measured in
a standard aluminium pan (40 lL) and heated from 25 to
300 C at a heating rate of 5 C/min under a constant purge
of argon at 10 L/h.
FT-IR
Samples with a LOR content of 0.5 mg were ground and
mixed with 150 mg of dry KBr in an agate mortar, and the
mixture was then compressed into a disc at 10 t. Each disc
was scanned 64 times at a resolution of 4 cm-1 over the
wave number region 4,000–400 cm-1 with an FT-IR
spectrometer (Thermo Nicolet AVATAR 330, USA). The
evaluation was carried out with the GRAMS/AI Ver. 7
program.
Study the effect of pH on the solubility
Seven buffer solutions were prepared with different pH
values between 1.2 and 7.5 [11]. The defined daily dose of
LOR is 10 mg, so 10 mg of LOR or the selected product
containing 10 mg of LOR was examined in 900 mL of dis-
solution media at 37 C. The paddle was rotated at 100 rpm.
After 2 h the removed samples were filtered and the LOR
concentrations were measured spectrophotometrically.
Results and discussion
Preliminary experiments
The results were compared with the data on the CD-free
system (see Table 1). The best solubility enhancement was
achieved with DIMEB, which resulted in an *300-fold
increase in solubility, and accordingly this derivative was
used in the further examinations.
Phase-solubility studies
A relevant diagram is shown in Fig. 1, the solid line
indicating the best linear regression fit of the experimental
data. Higuchi and Connors [3] defined two main types of
diagrams. In general, type A is characteristic for the water-
soluble CD derivatives, while type B is observed for the
less-soluble natural CDs. In type A, the solubility of the
drug increases with increasing CD concentration. B-type
phase-solubility profiles reflect the formation of complexes
with limited solubility in aqueous medium. Type A has
three subtypes (AN, AL and AP). The subtype of the present
diagram is AL. The most common type of CD complexes
are the 1:1 drug:CD complexes. However, a slope of\1 for
a type AL diagram does not necessarily indicate that only a
1:1 complex is formed, though this is a common assump-
tion. The stability constant (K1:1) of the complex can be
calculated from the slope and the intrinsic solubility of the
drug in the aqueous medium (see Eq. 1). In the absence of
Table 1 Effect on solubility enhancement of CD derivatives
c (lg/mL) Solubility
enhancement (-fold)
LOR 2.43 1.00
? a-CD 23.69 9.75
? c-CD 34.73 14.29
? Captisola 80.05 32.94
? HP-b-CDb 128.14 52.73
? H-Bu-b-CDc 181.69 74.77
? b-CD 212.02 87.25
? RAMEBd 496.89 204.48
? Me-b-CDe 592.62 243.88
1 DIMEB 730.87 300.77
a Sulfobutyl-ether-b-CD
b 2-Hydroxypropyl-b-CD
c Hydroxybutyl-b-CD
d Random methylated-b-CD
e Methyl-b-CD
Fig. 1 Phase-solubility diagram of LOR at pH 7.5
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DIMEB, the equilibrium water solubility of LOR (S0) was
determined to be 0.81 ± 0.14 mg/L. For LOR the K1:1
value is very large: 1.48 9 106 M-1. From linear regres-
sion, r2 is 0.9991.
K1:1 ¼ slope
S0ð1  slopeÞ ð1Þ
In vitro dissolution studies
According to the pKa value the solubility of LOR depends
on the pH: it exhibits good dissolution in acidic medium
(e.g. SGM), but dissolves poorly in alkaline medium (e.g.
SIM). The presence of DIMEB did not alter the good
solubility in SGM: the total investigated amount of the
sample dissolved in the first 5–10 min, independently of
the preparation method and the composition. As concerns
the dissolution in SIM, the rate of dissolution was
improved for all of the products, but the extent of this
increase depended on the preparation method and the molar
ratio. For the 1:1 compositions (Fig. 2), none of the prep-
aration methods resulted in 100% dissolution. The lowest
solubility enhancement was observed for the PM (8.7-fold),
as expected, because this mode of preparation does not
generally result in a complex. The KP furnished a 67.6-fold
solubility increase, but the best enhancement was achieved
with the SD (142.9-fold). For the 1:2 preparations (Fig. 3)
the PM displayed similar results as for the 1:1 product, with
only a slight further improvement in solubility (10.26-
fold). For the KP and SD 1:2 products, the whole of the
investigated samples dissolved in the first 15 min, i.e. the
dissolution in SIM was as good as in SGM, which means
that the same good dissolution would be attained at the
extreme pH values of the gastrointestinal tract on the use of
these DIMEB products. Accordingly, the rate-limiting step
of absorption would not be the dissolution: the perme-
ability would regulate the passage through the membrane.
As LOR has good permeability, the application of LOR
complexed with a CD such as DIMEB would lead to a
greater quantity of drug being absorbed, so that better
bioavailability would be obtained.
DSC results
The sharp, narrow endothermic peak in the DSC spectrum of
LOR (peak 133.16 C, normalized melting enthalpy
89.48 J g-1) denotes the melting point of the material. The
stability of LOR was not affected (no degradation was
observed) up to 300 C. Our DIMEB was amorphous, and
there was no thermoanalytical indication at the melting
point of LOR, but there was an exothermic peak reflecting
the recrystallization of DIMEB at 181 C. Above 320 C, a
broad endothermic peak was observed, associated with
decomposition of the material. The results for the 1:2
compositions are presented in Fig. 4. For the PM, the
melting point of LOR was seen several degrees lower than
for pure LOR (this is characteristic for CD complexes) and
the area under the peak was proportional to the amount of
LOR in the sample. Hence, no inclusion complexes were
formed in the PM product. For the KP and SD samples, no
endotherm reflected the melting point of LOR. Accordingly,
the KP sample exhibited total inclusion complexation, but
Fig. 2 Dissolution of 1:1 products in SIM
Fig. 3 Dissolution of 1:2 products in SIM
Fig. 4 DSC curves of LOR and 1:2 products
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for the SD sample it is possible that the product was amor-
phized or that total complexation occurred during the
preparation.
FT-IR studies
The spectral changes were evaluated by subtraction of the
spectrum of DIMEB from the spectra of the samples. The
spectrum of LOR and the calculated subtraction spectra of
the 1:2 products are presented in Fig. 5. The spectra of
the products involving different molar ratios and prepa-
ration methods did not differ appreciably. The difference
spectrum of the PM product was practically identical to
the spectrum of pure LOR, indicating negligible interac-
tion between LOR and DIMEB. For the KP and SD
samples, the characteristic C=O stretching frequency
(1,702 cm-1) was shifted to lower wave numbers, and the
typical C–O stretching at 1,227 cm-1 was shifted to
higher range. In accordance with the DSC finding, in the
KP 1:2 product, total complexation occurred, and FT-IR
also revealed total complexation for the SD sample. These
results lead us to surmise that the –COO group provides
the complex-forming bonds to the outer surface of
DIMEB and that complex formation alters the hydrogen-
bonded cyclic dimeric structure involving the carboxyl
group. During the formation of the inclusion complex,
hydrogen-bonds develop between LOR and DIMEB, and
the inclusion complex can therefore be regarded as co-
crystals [25]. A lipophilic part of LOR will probably be
attached to the inner surface of DIMEB, like the aromatic
rings, but in the FT-IR spectrum of LOR, the character-
istic stretching frequencies of these aromatic parts are
masked by DIMEB, so these connections can not be
detected with this method.
Study of the effect of pH on the solubility
The defined daily dose of LOR is 10 mg. In view of the
results of the preliminary studies, we chose DIMEB to
examine how the solubility of LOR from the LOR:DIMEB
1:2 products depends on the pH. The PM products exhib-
ited only 2–6% dissolution; both DSC and FT-IR proved
that this preparation method did not result in inclusion
complexes. The KP and SD methods gave products which
displayed similar results in the dissolution tests. However,
the KP method is simpler and easier to scale up than the SD
method, so our choice was the KP 1:2 product. We then
investigated the solubility of 10 mg of pure LOR and of the
KP 1:2 product containing 10 mg of LOR in the different
buffer solutions. The solubility of LOR has been reported
to decrease with increasing pH [11]. As can be seen in
Fig 6, the applied dose of pure LOR did not dissolve at the
pH of intestines, from where it is absorbed. In contrast,
virtually the whole quantity of LOR dissolved from the KP
1:2 product at each pH value. This clearly suggests an
opportunity to ensure smooth dissolution for LOR, thereby
achieving better and more uniform bioavailability.
Conclusions
CDs are capable of improving the solubility and dissolution
of poorly water-soluble drugs such as LOR. Depending on
the preparation method and molar ratio the solubility of
LOR was enhanced *200-fold. The DSC and FT-IR
results demonstrated that DIMEB forms total inclusion
complexes with LOR through hydrogen-bonding with the
carboxyl group.
The solubility of LOR was made independent of the pH
within the range of gastrointestinal pH through the appli-
cation of DIMEB at a LOR:DIMEB composition of 1:2
with preparation by KP methods, so that the bioavailability
will probably be better and smoother. For this purpose, we
would like to carry out in vivo studies.Fig. 5 FT-IR spectras of LOR and 1:2 products
Fig. 6 pH-dependence of LOR and KP 1:2 product
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a b s t r a c t
A tricyclic, piperidine derivative of antihistamines, loratadine, which belongs in class II of the Biopharma-
ceutical Classiﬁcation System, was investigated. It is an ionizable drug, whose solubility depends on the
gastrointestinal pH, and the bioavailability is therefore very variable. Inclusion complexes were prepared
by kneading method, containing loratadine (LOR) and dimethyl--cyclodextrin (DIMEB) in two different
molar ratios in an attempt to achieve better dissolution and therefore the better bioavailability of lorata-
dine. The formation and physicochemical properties of the inclusion complexes were investigated by
means of dissolution tests, pH-dependent solubility studies, electrospray ionization mass spectrometry
and diffusion-ordered 1H NMR spectroscopy. The in vivo efﬁciency of the complexes was examined in
rat animal experiments to conﬁrm the better in vitro dissolution. The instrumental examinations proved
the presence of total complexes in 1:1 ratio in both compositions. However, the in vitro pH-dependent
solubility results, the in vivo blood levels and the greater pharmacological effect prove that excess DIMEB
is needed to achieve the pH-independent and complete solubility of LOR, and therefore better and more
consistent bioavailability.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
One of the prerequisites for successful oral drug therapy is
sufﬁcient intestinal absorption. The rate and extent of intestinal
absorption aremainly dependent on thedissolution rate of thedrug
in the gastrointestinal ﬂuids and the rate of transport across the
intestinal membrane [1]. These two factors form the basis of the
Biopharmaceutical Classiﬁcation System (BCS) [2]. If the drug is an
ionizable compound, the intestinal absorption depends on its pKa,
too [3]. Poorly water-soluble drugs (BCS classes II and IV) are asso-
ciated with slow drug absorption, leading eventually to inadequate
and variable bioavailability (BA) [2,4].
Loratadine (LOR), chosen for the current studies, is a BCS class
II drug [5], with dissolution- or solubility-limited absorption. It is a
second-generation antihistamine. LOR is a weak base; its pKa value
at 25 ◦C has been reported to be 4.85–6.00 [5–8]. The solubility of
bases increases with decreasing pH at pH values less than the pKa
[9]. However, according to the modiﬁed Hendersson–Hasselbach
equation [10], bases are totally ionized at lower pH values, and at
∗ Corresponding author. Tel.: +36 62 545577; fax: +36 62 545571.
E-mail address: aigner@pharm.u-szeged.hu (Z. Aigner).
∼pH 7 and higher they are totally non-ionized, which is the form
able to be absorbed. Thus, LOR will probably be absorbed from the
intestines, in which it exhibits poor solubility.
The main objective of the present study was to investigate
the stoichiometry of two inclusion complexes (kneaded products
(KPs) 1:1 and 1:2) and the anti-inﬂammatory effects of LOR and
these complexes in vitro (Parallel Artiﬁcial Membrane Permeabil-
ity Assay – PAMPA model) and in vivo (rat). Our earlier studies
[11] revealed that complexation with dimethyl--cyclodextrin
(DIMEB) (at some compositions) resulted in pH-independent sol-
ubility for LOR; at the pH, where LOR is totally non-ionized
and hence able to be absorbed, the complexed LOR dissolves
about 10 times better than in the absence of DIMEB. The aim
of this study was to conﬁrm this observation in vivo. Many
studies have been published on the pharmaceutical applica-
tions of cyclodextrins (CDs) and primarily on their ability to
improve the solubility and dissolution rate of poorly soluble drugs
[12,13].
Electrospray ionization mass spectrometry (ESI-MS) and
diffusion-ordered 1H NMR spectroscopy (DOSY) provide powerful
techniques to analyse the stoichiometry of supramolecular com-
plexes like CD inclusion complexes [14]. By the PAMPA model the
characteristics of passive diffusion can be investigated. Therewith
0731-7085/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.jpba.2011.01.024
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performing an in vivo experiment in vitro/in vivo correlation can be
predicted.
2. Materials and methods
2.1. Materials
LOR was kindly provided by TEVA Ltd., Hungary. Heptakis-
2,6-di-O-methyl--CD (DIMEB-50, 50% isomeric purity, DS∼14)
was purchased from Cyclolab Ltd., Hungary. Compound 48/80
(N-methyl-4-methoxy-phenethylamine) was supplied by
Sigma–Aldrich Logistic GmbH, Germany. Other chemical reagents
were of analytical grade purity.
2.2. Preparation of the products
The KPs were prepared in two molar ratios (LOR:DIMEB=1:1
and 1:2). The physical mixtures were suspended in the same mass
of 50% ethanol, and the solvent was evaporated off at room tem-
perature. After drying, the productswere ground. All of the samples
were sieved (100m) and stored at room temperature under nor-
mal conditions.
2.3. Diffusion-ordered spectroscopy (DOSY)
Diffusion coefﬁcients (D) were estimated via DOSY NMR exper-
iments. In the DOSY spectra, chemical shifts were located along
the F2 axis and D values along the F1 axis. From the D values, it is
possible to infer the size of the species and therefore the absolute
stoichiometry of the supramolecular complexes.
TheNMRspectrawere recorded at 25 ◦ConaBrukerAvanceDRX
400MHz spectrometer. For 2DDOSY 1HNMR, pulsedﬁeld-gradient
spin-echo NMR measurements were performed by using the stim-
ulated echo and longitudinal eddy current delay (LED) sequence
[15]. A time of 1.5ms was used for the dephasing/refocusing gra-
dient pulse length (ı), and 100ms for the diffusion delay (). The
gradient strength was changed quadratically from 5% to 95% of the
maximum value (B-AFPA 10 A gradient ampliﬁer), and the number
of steps was 16. Each measurement was run with 32 scans and 16K
time domain points. For the processing, an exponential window
function and single zero ﬁlling were applied. During the diffusion
measurements, the ﬂuctuation of the temperaturewas <0.1K. Prior
to the NMR scans, all the samples were equilibrated for 30min. The
data were analysed by using XWINNMR 2.5 software.
2.4. Electrospray ionization mass spectrometry (ESI-MS) studies
ThecompoundswerecharacterizedbyMS,usingaFinniganMAT
95S sector ﬁeld mass spectrometer equipped with an electrospray
ion source. Positive-ion ESI-MS spectra were obtained. The solu-
tions were prepared in a 1:1 mixture of acetonitrile/water. The
solutionswere infused directly into themass spectrometer at a rate
of 200lmin−1. Data were collected for approximately 100 scans.
The scan range was 100–3000m/z. The spectrometer was used at a
resolution of ∼1000–1500.
2.5. In vitro dissolution study
The modiﬁed paddle method with the USP dissolution appa-
ratus (Erweka Type DT, Germany) was used to examine 200mg
samples of pure LOR or products containing 200mg of LOR in
100ml of simulated intestinalmedium (SIM) (pH7.0±0.1; 14.4 g of
Na2HPO4·2H2O and 7.1 g of KH2PO4 made up to 1000ml with dis-
tilled water). The paddle was rotated at 100 rpm and sampling was
performed up to 120min (sample volume 5.0ml). Aliquots were
withdrawn at 5, 10, 15, 30, 60, 90 and 120min and immediately ﬁl-
tered. At each sampling time, an equal volumeof freshmediumwas
added, and the correction for the cumulative dilution was calcu-
lated. After ﬁltration and dilution, the LOR contents of the samples
were determined spectrophotometrically (SIM =248nm).
2.6. Study of the effect of pH on the solubility
Seven buffer solutions were prepared with different pH values
between 1.2 and 7.5 [16]. The deﬁned daily dose of LOR is 10mg, so
10mg of LOR or a product containing 10mg of LOR was examined
in 900ml of dissolution medium at 37 ◦C. The paddle was rotated
at 100 rpm. After 2h, the removed samples were ﬁltered and
the LOR concentrations were measured spectrophotometrically
(pH 1.2, 2.0, 2.5, 3.0 = 276nm; pH 4.5 = 244nm; pH 6.5, 7.5 = 248nm).
2.7. PAMPA
PAMPA “sandwiches” were formed from a donor 96-well
microtitre plate (MilliporeMATRNPS50) and amatchingﬁlter plate
(Millipore Multiscreen®-IP, MAIPNTR 10) with an apparent poros-
ity of 0.45m, coated with 5l of a 1% (w/v) n-dodecane solution
of lecithin. The initial donor sample concentrations were about
150M. The plate sandwich was allowed to incubate at 25±1 ◦C
for 16h without stirring, in an atmosphere saturated in humidity.
Afterwards, sample concentrations in both the acceptor and donor
wellswere determined byHPLC. Effective permeability coefﬁcients
(Pe) were determined by taking into account the apparent ﬁlter
porosity and sample mass balance.
The donor (150l) and acceptor (300l) compartments both
contained pH 7.4 buffer solutions. The permeability rates were cal-
culated by using the following equation:
log Pe = log
{
C · − ln
(
1 − [drug]acceptor
[drug]equilibrium
)}
with
C = VD · VA
(VD + VA) · A · t
where VD, volume of the donor compartment (ml); VA, volume
of the acceptor compartment (ml); A, active surface area of the
membrane (0.24 cm2 in the case of the applied ﬁlter plate); t, incu-
bation time for the assay (s); [drug]acceptor, concentration of the
compound in the acceptor compartment at the completion of the
assay; [drug]donor, concentration of the compound at theoretical
equilibrium.
2.8. In vivo experiments
This study was approved by the Committee on Animal Research
at the University of Szeged (IV./01758-6/2008). A colony of inbred
150±5g male Wistar rats (Charles River Laboratories, Germany)
was used, fed commercial rodent pellets and tap water. The ani-
mals were housed in groups of 5 at a controlled room temperature
(22±1 ◦C) andmaintainedunder an alternating12h light/12hdark
cycle (light on at 6:00 am).
The following materials were tested in this study: LOR, DIMEB,
KP 1:1 and KP 1:2 (LOR:DIMEB). The test substances were
given orally in suspension in 0.25% methylcellulose in a dose of
10mgkg−1 (1.00ml kg−1).
The animalswere divided into ﬁve groups,with 6 rats per group.
Group I received the vehicle and served as a control. To study the
inﬂuence of DIMEB on the oedema, the Group II animals received
DIMEB. LOR, KP1:1 andKP1:2were administered to theother three
groups, respectively.
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In these experiments, at ﬁrst the animals were treated orally
by the above mentioned suspensions. 1h later the histamine lib-
erator compound 48/80 in physiological solution (10g/0.1ml)
was administered subplantarly to elicit the inﬂammatory reac-
tion [17,18]. In light isoﬂurane narcosis the intensity of the arising
inﬂammatory reactionwasmeasured after 30minwith the use of a
plethysmometer (Ugo Basile, Harvard Apparatus, Germany) on the
basis of the volume difference between the right hind leg treated
with compound 48/80 and the left hind leg treated with vehi-
cle (physiological saline). Immediately after measuring the extent
of the oedema, blood samples were taken from rats by cardiac
puncture and collected in tubes containing sodium ethylenedi-
aminetetraacetate. Then these samples were centrifuged and the
obtained plasmas were frozen until the measurement of LOR-
content (see below).
Ahigh-performance liquid chromatographic (HPLC)methodhas
been developed for quantitative analyses of LOR in in vitro (PAMPA
model) and in vivo samples.
HPLC measurements were performed with a JASCO PU-
1580 binary pump (JASCO Inc., Japan) and a programmable
variable UV–visible detector. LOR was chromatographed on a
100mm×4.6mm i.d., 3m particle, Phenomenex Luna C8(2),
100 A˚ analytical column under reversed-phase conditions at 30 ◦C,
protected with a SecurityGuard Cartridge (4.0mm×2.0mm) pre-
column. Thedegassedmobilephasewas a47:42:11 (v/v)mixtureof
acetonitrile, puriﬁed water and a phosphate buffer solution (0.5M,
pH3.0±0.1, adjusted by the addition of 85% orthophosphoric acid).
The ﬂow rate was 1.0mlmin−1 and the analyte was monitored at
250nm.
Calibration plots were constructed by analysis of working solu-
tions (concentrations of 5, 10, 25, 50 and 75gml−1 (in vitro) and
5, 10, 50, 75 and 100ngml−1 (in vivo)) of LOR in the mobile phase
and plotting concentration against peak-area response for each
injection. The calibration curves were linear throughout the whole
range tested and described by the equations y=20.318x–23,775
(R2 =0.9912) and y=1083.4x+31.777 (R2 =0.9957) for the in vitro
and in vivo measurements, respectively. Unknown samples were
quantiﬁed by reference to these calibration plots. Inter-day pre-
cision was calculated from results on the calibration sample of
5gml−1 analysed on 20 consecutive days (n=5). The mean
amount found was 4.98gml−1 and the RSD value was 2.47%.
The limits of detection (LOD) and quantiﬁcation (LOQ) were deter-
mined on the basis of the S.D. of the response (y-intercept) and the
slope of the calibration plot. LOD and LOQ for LOR were 0.004 and
0.013gml−1, respectively.
500l of mobile phase was added to 500l of plasma, and this
mixture was then centrifuged at 17,000 rpm for 15min. The clear
supernatant was next collected and ﬁltered through a 0.22m
membrane ﬁlter (Millipore). From this solution, a 100l aliquot
was injected for HPLC analysis.
Statistical analyses were performed with Prism 4.0 software
(GraphPad, San Diego, CA, USA). Differences in paw oedema
between the treatment and control groups were determined by
one-way analysis of variance (ANOVA) with the Newman–Keuls
post hoc test. The criterion for statistical signiﬁcance was taken
as p<0.05. An experimental group contained 6 rats. All values are
expressed as mean± S.E.
3. Results and discussion
3.1. ESI-MS results
ESI-MS is the most promising tool for the characterization of
different kinds of host–guest complexes in the gas phase [19]. It
can provide evidence of complexation and stoichiometry on the
basis of themolecularweights of all vaporized species. The study of
host–guest interactions in thegasphaseallows thedetectionof spe-
ciﬁc interactions not necessarily present in solution, thereby giving
a complementary picture of the intrinsic phenomena responsible
for molecular recognition. Also, there are interpretation ambigui-
ties as concerns the ESI-MS spectra of supramolecular assemblies,
e.g. deciding whether the species present in the mass spectra cor-
respond to those present in solution, or they rather result from
processes occurring under high-vacuum conditions. Moreover, it is
not clear whether the molecular ions observed are real inclusion
complexes or only ion-dipole external adducts, i.e. “false positives”
[20]. In our particular case, however, a comparison can easily be
made with the aid of results obtained from independent solution-
phase techniques.
The hydroxyl groups of CDs are not easily protonated or depro-
tonated; ESI-MS analyses are usually carried out in the presence of
salts in order to enhance detection.
The positive ESI spectra of KP 1:1 and KP 1:2 are reported in
Fig. 1a and b, respectively.
An interesting feature of the ESI-MS binding of the analytes
with the CDs is the reproducible loss of water. This water loss is
presumed to arise from displacement of water from the CD cavity.
Host–guest complexes formed in solution are also stable for
characterization by ESI in the gas phase.
The ESI of DIMEB with positive ion detection leads to a series
of protonated molecules, [M+H]+, at m/z values depending on the
number of methyl groups in each individual sugar unit of the CD
derivative. The mass spectra reﬂect the average distribution of the
methyl groups of DIMEB. It should be noted that the ion peak at
m/z 1331 corresponds to 14 O-methyl groups (i.e. heptakis(2,6-di-
O-methyl)cyclomaltoheptaose to a ﬁrst approximation) [21].
As expected, the spectrum essentially involves peaks due to
singly charged ions of pure LOR [at m/z 383 as (LOR)H+] and pure
DIMEB [at m/z 1331 as (DIMEB)H+]. A new signal corresponding to
the inclusion complex as a singly charged ion (DIMEB+LOR)H+ is
observed at m/z 1730.
When the mixtures with different molar ratios (1:1 or 1:2) of
LOR and DIMEB were analysed by ESI-MS, only the 1:1 complex
was found in all the mass spectra, which suggests that the DIMEB
inclusion complex in the gas phase has a certain stoichiometry.
3.2. DOSY results
The D value observed in the NMR experiment (fast-exchange
condition) is the weighted average of those of the bound and the
free guest. The rationale behind the extraction of the bound frac-
tion from diffusion NMR measurements is simple. The host and
guest have their own D values in the free state, reﬂecting their
molecular weight and shape. The guest molecules are signiﬁcantly
smaller than CD, and the D values of the bound guests were taken
to be equal to that of CD; it was assumed that, for the binding of a
small guest molecule to a large host molecule, the D value of the
host is not greatly perturbed and that of the host–guest complex
can be assumed to be the same as that of the non-complexed host
molecule. In the case of a weak or negligible association, the D val-
ues of the host and the guest will remain unchanged. For any other
case, assuming fast exchange on the NMR time scale, the observed
(measured) D values are weighted averages of the free and bound
D values [22].
In the 2D DOSY spectra (Fig. 2), the F2 dimension shows the
chemical shift and F1 stands for logD. Groups belonging to the same
molecule will therefore appear in almost the same F1 row.
In the molecule of DIMEB, there are CH2 groups and –O–CH3
groups, which have chemical shifts (ı) in the range 1–5ppm. In the
molecule of LOR, there are aromatic protons which have higher ı
values, at about 7–8ppm. In the DOSY spectrum of KP 1:1, logD
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Fig. 1. ESI-MS results on KP 1:1 (a) and KP 1:2 (b).
is the same for every chemical shift, which is possible only when
LOR is complexed in DIMEB, when they compose a unit. If LOR
is not complexed, it should diffuse more quickly due to its small
molecular weight; it should have a smaller D value.
The D value measured for the complex indicates that it is best
formulated as the 1:1 complex. For perfect spheres, theory predicts
that increasing themolecularweight n-fold should lead to aD value
decreasedby a factor ofn−1/3. Unfortunately, in the absence ofwell-
deﬁned 1H NMR spectra, X-ray crystallographic results or ESI-MS
data, assignment of absolute stoichiometry to these aggregates is
speculative [23].
Fig. 2. Representative DOSY spectra of KP 1:1 (grey) and KP 1:2 (black).
3.3. In vitro dissolution study
According to the pKa value, the solubility of LOR depends on
the pH:LOR can undergo protonation on the N of the pyridine ring
in acidic media, forming salts with good solubility. It therefore
exhibits good dissolution in acidic media, but dissolves poorly in
alkaline media (e.g. SIM).
The rate of dissolution was improved for all of the products,
but the extent of the increase depended on the molar ratio (see
Fig. 3). For the KP 1:1 composition, the dissolution of LOR did
not reach in 100%: only 70% of the LOR dissolved during 2h. For
KP 1:2, the whole of the investigated samples dissolved in the
ﬁrst 15min, i.e. the dissolution in SIM was as good as in acidic
media, which means that the same good dissolution would be
attained at the extreme pH values of the gastrointestinal tract on
the use of this DIMEB product. Accordingly, the rate-limiting step
of absorption would not be the dissolution: the passage through
the membrane would be regulated by the permeability. As LOR
has good permeability, the application of LOR complexed with
a CD such as DIMEB in 1:2 molar ratio would lead to a greater
quantity of drug being absorbed, so that better BA would be
obtained.
3.4. Effect of pH on solubility
The deﬁned daily dose of LOR is 10mg. The solubility of LOR has
been reported to decrease with increasing pH [5]. As can be seen in
Fig. 4, in the acidic range (to pH∼3) both the 1:1 and 1:2 compo-
sitions allow total dissolution of the applied dose. However, with
increasing pH, DIMEB is not able to dissolve the whole quantity in
the case of the 1:1 product, and the BA will therefore not be sufﬁ-
cient: only about 70% of the investigated amount of the 1:1 product
dissolved at higher pH. In contrast, virtually the whole quantity of
LOR dissolved from KP 1:2 at each pH value, proving the solubility
of LOR is independent of the pH. This clearly suggests an oppor-
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Fig. 3. Dissolution of LOR, KP 1:1 and KP 1:2 in SIM.
Fig. 4. Comparative solubility data of LOR, KP 1:1 and KP 1:2.
tunity to ensure consistent dissolution for LOR, thereby achieving
better and more uniform BA.
3.5. PAMPA
LOR is ahighlyvariabledrug fromtheaspectofBA: its absorption
depends greatly on whether the patient has eaten or not, and what
was eaten. In the fasted state, different enzymes andnatural solubi-
lizers (e.g. bile acids) are released, which help to dissolve the drug.
All forms of food have their own acidic (e.g. meats, cheese, egg,
alcohol, mustard, sweeties, etc.), basic (e.g. potato, carrot, onion,
mushroom or coconut) or natural characteristics, which inﬂuence
the pH in the GI tract, and hence the solubility of this ionizable API.
The pH of the stomach is known to differ signiﬁcantly among indi-
viduals and is within the range of 1–3 or even higher (1–5) under
fasting conditions. If undissolved LOR is emptied from the stom-
ach, the absorption rate will be dramatically lower as compared
with that in individuals where complete dissolution occurs in the
stomach [5].
As LOR is a BCS class II drug, it readily passes through
the intestinal wall, with a permeability value of 2.7×10−3 to
4.8×10−5 cmmin−1 [5]. The PAMPAmodel represents only passive
diffusion, and deceptive results can be observed if other mecha-
nisms also play a role in the absorption of the API. LOR is a substrate
of P-gp, which hinders its absorption, and thus the BA of this
molecule. Fig. 5 indicates that LOR has higher permeability than
the DIMEB-containing products.
The results demonstrate that, if passive diffusion were the
main force of absorption, DIMEB would hinder this process. It is
possible that the diffusion through this artiﬁcial membrane is bidi-
rectional, and therefore the absorbed LOR can back-diffuse to the
donor side and become recomplexed by DIMEB. Another expla-
nation is that the stability of the complex is too high, and the
association–dissociation balance is shifted to association. There is
Fig. 5. Calculated effective permeability values of LOR, KP 1:1 and KP 1:2.
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Fig. 6. Oedema volumes in the treated and the control groups (signiﬁcance evaluations involve comparisons with LOR).
an observable relationship between the amount of DIMEB and the
calculated permeability. The higher the concentration of DIMEB,
the lower the permeability is. This conﬁrms the theory that the
association–dissociation balance is shifted to association, and the
back-diffused LOR is recomplexed by free DIMEB. The statistical
analysis reveals that the differences between the Pe values of LOR
and KP 1:1, LOR and KP 1:2, and KP 1:1 and KP 1:2 are signiﬁcant
(p<0.05).
The permeability of LOR increases with increasing pH: at acidic
pH, LOR is in a protonated form, which cannot pass through the
membrane, but at basic pH it is not protonated (non-ionized), and
can be absorbed. This tendency also holds for KP 1:2, but the per-
meability is always lower at each pH value, which corresponds to
the above discussion.
3.6. In vivo experiments
The main effect of the oedema inducer compound 48/80 is the
release of histamine from the mastocytes, and hence the effect
of the antihistamine LOR can be well examined with this model
[17,18].
LOR, DIMEB and the inclusion complexes were investigated to
establish to what extent they can reduce induced oedema. The vol-
umes of the oedema induced in the right back paws are presented
in Fig. 6. It was found that DIMEB did not inﬂuence the extent
of oedema relative to the control group, and thus the effects of
the DIMEB-containing products can only be due to the LOR in the
products. Rats pretreated with LOR, KP 1:1 and KP 1:2 signiﬁcantly
decreased the compound48/80-induced oedema. The results of the
Newman–Keuls multiple comparison test are presented in Table 1.
It is evident that the abilities of LOR, KP 1:1 and KP 1:2 to decrease
oedema differ signiﬁcantly; the complexation of LOR with DIMEB
resulted in better BA.
We also measured the blood concentrations by HPLC. The data
shown inFig. 7 relate to theeffects onoedema, except that theblood
Table 1
Results of the Newman–Keuls multiple comparison test.
Comparisons Mean difference Q p value
Control vs. DIMEB −2.333 1.097 >0.05ns.
Control vs. LOR −60.83 30.08 <0.001***
Control vs. KP 1:1 −70.33 33.08 <0.001***
Control vs. KP 1:2 −81.43 35.98 <0.001***
LOR vs. KP 1:1 −9.50 4.015 <0.01**
LOR vs. KP 1:2 −20.60 8.273 <0.001***
KP 1:1 vs. KP 1:2 −11.10 4.311 <0.01**
concentrations of LOR and KP 1:1 do not differ signiﬁcantly, which
demonstrates that KP 1:1 does not reach the desired BA. Excess
DIMEB (as in KP 1:2) is needed to obtain pH-dependent solubility
and more consistent and greater BA.
LOR was well separated from the biological background
under the described chromatographic conditions, with mean
RT=7.50min.No interferencewithplasmamatrix constituentswas
observed. The mobile phase used guaranteed good repeatability of
the retention times. The LORconcentration in samples fromtheani-
mals is about a fewngml−1, and thus the analyticalwavelengthwas
selected according to the maximum LOR absorbance with respect
to a stable baseline.
P-gp recognizes many compounds as substrates, and tends to
have high afﬁnity for hydrophobic and positively charged com-
pounds at physiological pH. DIMEB appears not to be a substrate
of P-gp because it is a hydrophilic and electrically neutral cyclic
oligosaccharide with a relatively high molecular weight. Further-
more, DIMEB should not compete with P-gp substrates due to its
lack of cell permeability. Thus, DIMEB must have an alternative
inhibitory effect on P-gp activity, differing from the P-gp inhibitors
that suppress the efﬂux by their surface activity. Some results sug-
gested that DIMEB has a direct inhibitory effect on the P-gp level on
the cell surface. DIMEB did not exhibit cytotoxicity on Caco-2 cells
and had no effect on the paracellular and transcellular transport
[24].
Hence, one part of the DIMEB will affect P-gp, and the other
part remains for the recomplexation. This can be another explana-
tion why there is a need for excess DIMEB to achieve much better
BA. These two mechanisms probably play a role in the enhanced
Fig. 7. Blood concentrations of LOR after oral administration of LOR and products
(signiﬁcance evaluations involve comparisons with LOR).
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absorption, and therefore the greater BA. So these observations also
suggested that the increase in the AUC value of LOR by DIMEB may
be caused not only by the solubilizing activity of DIMEB, but also
by inhibition of the efﬂux in the GI tract.
4. Conclusion
We have already demonstrated that DIMEB is able to make the
solubility of LOR independent of the pH. It has now been estab-
lished based on the ESI-MS and 1H NMR DOSY results that the
stoichiometry of the complex is 1:1. However, it is not enough
to obtain pH-independence. For the 1:2 product, the solubility
and the dissolution rate of LOR is higher and independent of pH
against the KP 1:1 product. This is also indicated by the in vivo
experiments, so better and more consistent BA can be achieved
due to complexation in the appropriate molar ratio. The knead-
ing method is one of the simplest complexation techniques; it
can easily be scaled up and is often used in preclinical formula-
tions.
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